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Chapter 1 details a background of techniques used for modeling the blood-brain 
barrier (BBB). The BBB represents a diffusive barrier to both paracellular and 
transcellular movement of many compounds in and out of the brain.  The main rate- 
limiting barriers of the BBB include exclusive tight junctions that prevent the movement 
of hydrophilic molecules through intercellular gaps, and efflux proteins in the membrane 
which pump many hydrophobic molecules back into the blood. In addition, the BBB 
contains metabolizing enzymes, including Cytochrome P450s. This barrier acts to protect 
the vulnerable tissues of the brain from harmful xenobiotics, but also can serve as a 
restrictive barrier for potential therapeutic compounds for the growing number of 
neurological diseases, including Alzheimer’s disease, Parkinson’s disease, stroke, 
depression, brain cancers, and many others.  In fact, it is estimated that over 98% of 
pharmaceutical compounds are unable to cross into the brain. Due to this problem, many 
compounds must be screened in order to determine their BBB permeation and eventual 
druggability.  While in vivo testing in pre-clinical animals and humans is ideal for testing, 
these methods aren’t suitable for early screening because of their high cost, low 
throughput, and ethical considerations, especially in humans.   
xv 
 
Therefore, a number of in vitro cell screens have been established to mimic the 
BBB for permeation testing.  Principally, the best model should include primary human 
brain microvessel endothelial cells (BMECs), however, due to the growing interest in 
BBB permeation and lack of tissues, the supply is limited.  As an alternative method, 
many groups have investigated the use of primary animal BMECs, usually of murine, 
porcine, or bovine source.  These models prove effective at restricting paracellular 
movement; however, one must question the effects of animal isoforms on modeling 
uptake, efflux, and metabolism of transcellular markers.  This proves important as in vivo 
most, if not all, therapeutic compounds will cross the BBB transellularly.  Consequently, 
much work has been done to establish immortalized human BMECs.  These immortalized 
cell lines alleviate the high cost and lack of supply found with primary human cells, but 
potentially may serve as a better model for transcellular permeation over animal cell 
lines.  Currently, the most widely characterized immortalized human BMEC cell line is 
the human cerebral microvessel endothelial cell line (hCMEC/D3).  These cells express 
tight junction proteins, efflux proteins, cyp450 enzymes, and are conducive to in vitro 
testing.  However, while these cells express tight junctions, their function is less than 
ideal and leads to a leaky monolayer which may allow faster permeation through the 
paracellular route or paracellular permeation of compounds that move transcellularly in 
vivo leading to poor prediction of BBB permeability.   One method of investigating the 
reason behind these leaky tight junctions was to take a closer look at the BBB itself.   
Closer examination shows that while the endothelial cells of the BBB form the 
main permeation barrier, these cells are surrounded by supporting cells such as astrocytes 
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and pericytes.  These cell lines are thought to promote proper differentiation of 
endothelial cells in vivo, therefore, some groups have moved to co- and triculture models.  
In these models, the supporting cells are plated on the basolateral side of a Transwell® 
support and/or on the bottom of the well plate.  After a given time, endothelial cells are 
then plated on the apical side of the Transwell® and the cells are allowed to grow together 
in the same medium.  Due to the nature of the filter support, this allows crosstalk of 
soluble factors between the endothelial cells and the supporting cells.  In practice, this 
often leads to decreased paracellular permeability and increased expression of tight 
junction proteins.  However, while having increased tightness, these models are still 
leaky in comparison to in vivo conditions and even primary BMECs.  
It is hypothesized that one reason for the continued lack of tightness may be due 
the lack of direct contact between endothelial and supporting cells.  While the Transwell® 
filter support allows movement of soluble factors between the compartments, the distance 
between cell layers is significantly higher than that found in vivo.  This increased distance 
may allow for increased dilution and degradation of soluble factors, reducing their 
potency.  In addition, the supporting cell lines are believed to secrete an extracellular 
matrix (ECM) which also helps to promote differentiation.  By splitting the cell lines with 
the Transwell®, the endothelial cells are unable to interact with this secreted matrix.  
Therefore, Chapters 2 and 3 discuss the optimization and establishment of a direct contact 
coculture in vitro model in which both endothelial cells and astrocytes are plated on the 
apical side of the Transwell® allowing for more physiologically relevant signaling 
between the cells.  Early results suggest decreased paracellular permeation in this 
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configuration compared to endothelial monocultures and indirect cocultures.  In addition, 
this setup should allow for easier transition to high-throughput equipment. 
Additional studies in Chapter 4 attempt to show the utility of a new mono-
PEGylated Human Serum Albumin (HSA) as a potential enhancer of drug solubilization, 
permeation, and eventual cytotoxicty.  Multi-gram batches of short (5 kDa) and long (20 
kDa) PEG-HSA were synthesized with high efficiency (77%) and characterized in 
collaboration with Dr. Jonathan Mehtala and Dr. Alex Wei in the Department of 
Chemistry.  Furthermore, effects of PEG-HSA on permeation of paclitaxel through 
peripheral and BBB in vitro cell models as well as changes in cytotoxicity against MCF-7 
cells was investigated. 
Finally, Chapter 5 includes an investigation into the characterization, formulation, 
and in vitro/in vivo testing of a potent V-ATPase inhibitor known as Saliphenylhalamide.  
The V-ATPase is an endogenous protein that is responsible for acidifying intercellular 
compartments and has been targeted in the past with in vitro success for treatment of 
cancer and osteoporosis among other diseases.  However, here we investigate its use as 
an anti-viral therapeutic as acidification of endosomes by the V-ATPase is thought to be a 
critical step in replication of alpha viruses.  Initial characterization showed poor water 
solubility and acid liability.  Therefore, two solubility enabling formulations were created 







CHAPTER 1. MODELING THE BLOOD-BRAIN BARRIER 
 
1.1 The Blood-Brain Barrier 
 The blood-brain barrier (BBB) is an active barrier, which selectively controls 
molecular and cellular movement between peripheral blood flow and the brain.1 While 
preventing the movement of harmful xenobiotics from entering the brain, it also allows 
for selective uptake of endogenous substrates needed for optimal neuronal activity.2  
Integrity of the BBB is necessary for proper neuronal function and disruption of the 
barrier is very often associated with CNS-related diseases such as Alzheimer’s, 
Parkinson’s, epilepsy, schizophrenia, as well as many others.3  While proper maintenance 
and upkeep of the BBB is important for healthy living, the BBB also presents a major 
obstruction to delivery of pharmaceutical compounds to treat neurological and 
neurodegenerative disorders.4 
 The BBB’s effectiveness in excluding xenobiotics is often attributed to the brain 
microvessel endothelial cells (BMECs) that form the capillaries of the brain.5  These 
endothelial cells are significantly restrictive to both paracellular permeation of 
hydrophilic molecules, through the formation of exclusive tight junctions, and 
transcellular diffusion of hydrophobic molecules, through the presence of luminal efflux 
proteins and intracellular metabolizing enzymes.6 However, while they represent the rate-
limiting permeation step, histological analysis shows the presence of other cells at the 
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BBB, including astrocytes, pericytes, neurons, and microglia.  Further investigation into 
these cells has shown their importance in BBB development and upkeep.  Due to the 
cohesive nature of these cells, the group was termed the neurovascular unit.7 
 
1.2 The Neurovascular Unit 
 A cross-section of the BBB shows the coordination of the neurovascular unit and 
can be seen in Figure 1.1.  As noted, the initial and rate-limiting barrier in blood-to-brain 
permeation is the endothelial cells.  These cells, however, are wrapped in supporting cells 
which are thought to be the differentiating factor between BMECs and endothelial cells 
of the periphery.8  This was confirmed through in vivo animal experiments showing that 
growing brain grafts in the periphery lead to decreased paracellular tightness, while 
grafting peripheral tissues into the brain induced tightening of the endothelium.9 Here we 
look further into the roles of both the endothelial cells as well as some of the supporting 







Figure 1.1.  The Cellular Associations of Neurovascular Unit.  Modified From Abbott NJ, 
et al. 2010.10 
 
Endothelial Cells 
 The endothelial cells that form the capillaries of the BBB are different from those 
in the periphery in a number of ways. The first, as mentioned above, is a reduced 
paracellular permeability due to the presence of specialized tight junctions.11  In addition, 
the endothelium of the BBB is continuous and lacks fenestrations which further limits 
paracellular permeability.12 Permeability of even large hydrophobic molecules is 
restricted in comparison to the periphery due to reduction in both transcytosis and 
pinocytosis.13  The BMECs also contain a high number of energy-producing 
mitochondria in comparison to the periphery which allows for increased metabolism and 
transport.14  Finally, endothelial cells contain a higher density of nutrient, i.e. glucose and 
amino acid, and efflux transporters, i.e. p-glycoprotein, which allows for increased 
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selectivity of transcellular permeability.15  While these characteristics distinguish the 
BBB from the periphery, the manifestation of these properties is determined by 
interactions of the supporting cells of the neurovascular unit as discussed below. 
 
Astrocytes 
As mentioned above, the properties of BMECs are not intrinsic to the cells, but 
brought on through induction in the CNS environment.16 This induction is in part thought 
to be due to BMEC-astrocyte intercellular signaling. This hypothesis was confirmed 
through early in vitro studies which showed BBB-like differentiation in astrocyte-
conditioned media.17 This media is partially spent media in which astrocytes are 
temporarily grown in and contains soluble factors secreted by the astrocytes.  This 
suggests that paracrine signaling by the astrocytes is likely to be important.  However, 
further studies showed that additional BBB induction, i.e. decreased paracellular 
permeability and increased tight junction protein expression, was seen when astrocytes 
and BMECs were grown together separated by a filter support.18,19  This possibly 
suggests cross-talk between the astrocytes and BMECs is necessary for physiologically- 
relevant BMEC differentiation. 
 A number of studies have been conducted to delineate the agents which lead to 
astrocyte-induced BBB differentiation and maintenance.  Some of these signaling 




Figure 1.2. BMEC-Astrocyte Cell-Cell Signaling. LIF- Leukemia Inhibitory Factor, 
TGFβ-Transforming Growth Factor-β,  bFGF- Basic Fibroblast Growth Factor, ANG1- 
Angiopoetin 1, GDNF- Glial-Derived Neurotrophic Factor, ET- Endothelin 1, TIE2- 
Endothelium Specific Receptor Tyrosine Kinase 2, P2Y2- Purinergic Receptor, and 5-
HT- Serotonin . Modified From Abbott NJ, 2006.20 
 
 As can be seen in the figure, signaling occurs in both directions with astrocytes 
inducing BMECs through soluble factors such as basic fibroblast growth factor (bFGF) 
and vice versa with factors such as leukemia inhibitory factor (LIF) which is released by 
the endothelial cells to promote astrocyte differentiation. While the importance and 
function of these factors is under some debate, addition and removal of these markers in 
in vitro cell models leads to significant changes in physiological relevance.18,20,21 
It should also be noted that astrocytes are glial cells with a star-shaped 
morphology. This star shape is formed by the outgrowth of a number of processes which 
end at a portion of the cell known as the astrocyte end foot.  These end feet wrap 
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endothelial cells, covering almost the entirety of the capillaries basolateral surface area 
creating a large surface area in close contact.22 This may suggest that close interactions 
between the astrocytes and BMECs is important, and is the basis for the chapters 2 and 3. 
 
Pericytes 
 Early investigations of the BBB suggested that while other cell types were found 
in the neurovascular unit, the main cell line responsible for BBB induction was the 
astrocytes.23  However, recent in vitro studies suggest that the pericytes may also play a 
role as BMECs grown in coculture with pericytes sometimes show increased TEER 
values which are indicative of BBB induction.24 Interestingly, pericyte coverage is not 
uniform throughout the BBB and varies from approximately 30-100% depending on the 
location in the brain.  This may suggest varying roles throughout the brain.25 
Unfortunately, little is known about pericyte and endothelial cell interactions, 
though their close interaction suggests that pericytes may be important for the BBB 
phenotype.  Interestingly, pericytes are found throughout the vasculature and are thought 
to be important for structural stability and microcontrol of capillary blood flow.26  They 
also appear to play a role in regulation of BBB angiogenesis. In addition, recent 
investigation shows that the pericytes may produce much of the extracellular matrix 
responsible for supporting cell-cell interactions in the BBB as pericytes are known to 






 As it is not a cell-line and therefore not involved in active signaling, the 
extracellular matrix (ECM), also known as the basement membrane or basal lamina, is 
often thought of as a passive player in BBB differentiation.  However, the ECM serves as 
important site for adhesion of the cells of the neurovascular unit, keeping them in close 
contact.28  It also may be important for promotion of cell polarity.29  The ECM of the 
BBB varies in thickness and is thinner than that of the periphery ranging from 20-200 
nm.30 It consists of entwined protein sheets comprised of mainly collagen (mostly Type 
IV which is indicative of the BBB), laminins, nidogens, heparin sulfate proteoglycans 
(i.e. agrin).31  Interestingly, each of these proteins is mostly excreted by different cell 
lines, which suggests that interaction between different cells in the neurovascular unit 
may be important.32   
 Support for the importance of the ECM at the BBB can be seen in a number of 
disease states.  For instance, tumors of the brain are often absent of the astrocyte-
produced agrin.20  This is thought to play a part in the increased leakiness found in the 
vasculature feeding these tumors.  In addition, genetic mutations in Type IV collagen 
leads to brain hemorrhage in animal models.33  While this suggests that the ECM is 
important, the exact functions are still unknown.  One method of studying these 
interactions is through in vitro cell culture, however, the ECM used in these cultures is 
often much simpler than the complex matrix found in vivo.  This makes it difficult to 




1.3 Permeability Barriers of the Blood-Brain Barrier 
 As stressed above, the main feature of the BBB is its ability to act as a highly 
selective barrier to permeation into the brain.  This helps to protect the vulnerable 
neurons, while allowing permeation of nutrients needed for proper brain function.6  While 
nutrient uptake transporters are physiologically important and may be taken advantage of 
for drug delivery, this section will focus on barriers.  These barriers include, tight 
junctions which are responsible for preventing paracellular permeation of hydrophilic 
molecules, efflux transporters which pump hydrophobic molecules back into the blood 
preventing transcellular permeability, and drug metabolizing enzymes (DMEs) which act 
to break down and inactivate potentially harmful xenobiotics that manage to enter the cell 
cytoplasm.34 Potential routes of permeation are shown in Figure 1.3 below. 
 





Tight junctions are protein assemblies which form complex intramembranous 
strands.11  Complementary strands on neighboring cells interact through protein-protein 
interactions of integral membrane proteins, closing the gap between the cells.35  While 
found in other areas of the body including the kidney and intestine, the tight junctions of 
the BBB are the most exclusive and most abundant.5  In the brain, these tight junctions 
are known to exclude even small elemental ions such as Na+ and Cl-.  This restriction of 
ions leads to high in vivo transendothelial electrical resistance (TEER) of 1,500-2,000 
Ω*cm.2,20  This high electrical resistance is indicative of the BBB phenotype, and is often 
used as a marker for distinguishing BBB induction. The main function of the tight 
junctions is to prevent the movement of hydrophilic molecules by the paracellular route 
through cell-cell junctions.36  In addition, the tight junctions also promote cell polarity by 
preventing the diffusion of transmembrane proteins expressed on the apical and 
basolateral surfaces of the cell.37   
 The tight junctions are highly regulated and organized being composed of a 
complex interaction of both integral membrane proteins, i.e. occludin, claudins, and 
junctional adhesion molecules (JAMs), and intercellular accessory proteins , i.e. zona 
occludins (ZO) and cingulin, which can be seen in Figure 1.4.11  As mentioned above, the 
integral membrane proteins act as extracellular sites for cell-cell interactions, however, 
these proteins must be connected to the cytoskeleton by the cytoplasmic accessory 





Figure 1.4. Molecular Organization of the Tight Junctions. Modified From Neuwelt, et 
al. 200838 
  
Within the tight junction, different proteins are believed to have different roles.  
Claudins are believed to be the main protein responsible for sealing the tight junction 
through homo- or heterotypic binding.39  While well over 20 claudins are known, 
claudin-1, claudin-3, and particularly claudin-5 are thought to be responsible for the 
increased tightness found in the brain.11,39  Occludin proteins were once thought to be the 
main permeation barrier, however, knockout studies have shown only small changes in 
paracellular permeability in vivo, which are not indicative of a phenotype devoid of tight 
junctions.40  Instead, it is now thought that changes in occludin phosphorylation state may 
be important for regulating small changes in tight junction permeability.11 While not 
playing a physical role in actual permeability restriction, the intracellular accessory 
proteins are important for tight junction localization, formation, and function.  In fact, 





 While the tight junctions prevent paracellular permeation at the cell junction, the 
BBB is also impermeable to many hydrophobic molecules which must often transverse 
the barrier through passive transcellular permeation.3  In large part, this impermeability is 
due the dense presence of energy dependent ATP Binding Cassette (ABC) transporters 
known as efflux transporters shown in Figure 1.5.  These transporters use ATP to pump 
molecules out of the cell against their concentration gradients.41 The transporters are 
comparatively unspecific in comparison to their uptake counterparts, and act to pump a 
variety of different compounds.  In addition, they have a large overlap of substrates 
leading to reduced permeation of many compounds even if one efflux transporter is 
absent or knocked down.42  It is likely that these transporters evolved to prevent harmful 
toxins and xenobiotics from reaching the brain, however, these proteins now present a 





Figure 1.5. Efflux Proteins at the Blood-Brain Barrier.  Modified From Löscher. 2005.41 
 Looking at Figure 1.5, it is interesting to see that while a number of the most 
commonly cited efflux proteins such as P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP), and some multidrug resistance proteins (MRPs) are found on the luminal 
membrane of the endothelial cells, additional transporters are found on the abluminal 
surface facing the brain.41 This is likely to pump endogenous neurotrophic factors against 
their concentrations and kept within the brain.44  While these abluminal transporters may 
serve as a potential area for drug delivery exploitation, through both increased 
permeation across the endothelial barrier and reduced clearance from the brain, little 
investigation in this area appears in the literature.  Instead, most research is focused on 
overcoming luminal efflux. 
 In general, the more hydrophobic the molecule the more readily it permeates the 
BBB as can be seen in Figure 1.6. However, as mentioned above, the efflux proteins of 
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the BBB are notoriously promiscuous and in addition, many of these transporters are 
upregulated in various disease states.45  As indicated in the figure, while BBB 
permeability increases with the partition coefficient, so does the likelihood of being a 
substrate for efflux transporters.46  This further complicates drug development making 
early prediction through in silico and in vitro modeling imperative.  
 
Figure 1.6. Blood-Brain Barrier Permeability vs. Partition Coefficient.  Dark Colored 
Ovals Reflect Efflux and Uptake Markers. Modified From Begley, D.  2004.46 
 
Drug Metabolizing Enzymes 
 Drug metabolizing enzymes are a class of enzymes known to modify 
pharmaceutical compounds in a number of ways often leading to increased clearance and 
reduced potency. Drug metabolism is broken up into two categories known as Phase I 
and II.  Phase I metabolism (including oxidation, reduction, or hydrolysis) acts to 
introduce reactive/polar constituents into their substrates which often leads to increased 
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elimination.47  Phase II metabolism, on the other hand, utilizes molecular conjugation 
(i.e. methylation, acetylation, glucuronidation, etc) as opposed to molecular 
modification.48  Oftentimes, these routes of metabolism are used in conjunction with a 
site for Phase II conjugation being first formed through Phase I molecular modification.47 
 As can be seen in Figure 1.7, even if pharmaceutical compounds are able to 
permeate into the cell, a number of DMEs are present to potentially degrade them.  
Interestingly, expression of DMEs at the BBB is significantly different at the microvessel 
than in the cortex which may be due in part to the differences in endogenous 
metabolomic needs.49  In addition, while CYP3A4 is generally first thought of due to its 
high expression in the periphery, some suggest little expression is seen in the brain.  
Instead, high amounts of CYP1B1 are found compared to the periphery.34 It should also 
be noted, that in addition to BMECs, astrocytes are also thought to produce CYPs, though 





Figure 1.7. In Vivo mRNA Expression of Human Drug Metabolizing Enzymes at the BBB. 
ND-Not Detected,   NQ-Non-Quantifiable.  Results are from 7 patients. Modified From 
Dauchy, et. al. 2008.49 
 
1.4 In Vitro Models of the Blood Brain Barrier 
 Ideally, one would use in vivo animal models to predict disposition into the brain 
due the complexity of the BBB.  A number of techniques are available including 
intravenous injection, injection into the carotid artery, perfusion studies, and intracerebral 
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microdialysis.50,51 While these techniques are highly invasive and only possible in 
diseased patients and animal models, sampling of human cerebral spinal fluid (CSF) is 
possible for compounds which have reached clinical trials.  However, the correlation 
between disposition into the brain and CSF is debatable.52  Nonetheless, all of these 
studies are rather expensive and unrealistic especially for drug discovery and lead 
selection.  Therefore, in silico and in vitro models have been established to, at minimum, 
help rank order druggable candidates in discovery.  
 The simplest in vitro BBB models consist of cerebral microvessels in 
monoculture.  In these models, BMECs are plated onto microporous inserts, i.e. 
Transwell® filter supports.53  While human BMECs would be ideal, models often utilize 
primary cells of various animal origins including bovine, porcine, murine, rat, and 
monkey due to the high demand and low availability of human tissues.34  While these 
cells are often cheaper and easier to acquire, it is important to recognize potential species 
differences, which affect all routes of permeation.  For instance, many animal endothelial 
cells express over two-fold increases in claudin-5 as compared to human BMECs.54  In 
addition, many species express varying levels of efflux transporters, often with much 
higher P-glycoprotein expression and lower levels of BCRP and MRPs.55  Finally, 
expression differences in DMEs are speculated to be highly variable between species.56  
These changes can culminate in significant changes in BBB permeability prediction as 
shown in a recent study comparing rodent and human BBB models which predicted, on 




 In order to alleviate some of these issues, a number of groups have begun work in 
immortalization of human BMECs.  Immortalization of these cells allows for a more 
consistent phenotype over a longer number of passages, drastically increasing supply.  A 
few immortalized human BMEC cell lines are currently available including human 
cerebral microvessel endothelial cells (hCMEC/D3s), human brain microvessel 
endothelial cells (hBMEC), TY10 cells, BB19 cells, as well as a number of proprietary 
cell lines.58  However, all of these cell lines suffer from one significant detriment in an 
inability to prevent paracellular permeation, a hallmark of the BBB.58  Immortalized cell 
lines often suffer from low TEER which rarely reaches 150 Ohm*cm2, much lower than 
reported in vivo values (though it should be noted that these in vivo values are reported 
from animal specimens).34,59 In an attempt to increase TEER, some progress has been 
made through media optimization, different immortalization techniques, and primary cell 
culture selection; however, the largest increases have been seen through coculture with 
supporting cells of the neurovascular unit.8,16-18,24,53,57,60-65 
 Since it is believed that interactions between BMECs and supporting cells of the 
neurovascular unit are at least in part responsible for the BBB endothelial cell phenotype, 
it is somewhat unsurprising that lack of this interaction leads to poor in vitro relevance.  
As discussed above, while first studied to examine the role of supporting cells at the 
BBB, coculture with these cells has lead to increased tight junction complexity and 
function as well as upregulation of a number of transporters.16,20,21  For this reason, many 
studies now utilize co- and triculture in in vitro BBB permeability prediction.  A number 
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of setups have been reported including culture with astrocytes, pericytes, and/or neurons. 
Some of these models are shown in Figure 1.8. 
 
 Figure 1.8. In Vitro Transwell Co- and Triculture Models.  Cells are represented as 
Blue-Endothelial Cells, Purple-Pericytes, and Green-Astrocytes. 
While results have been somewhat inconsistent, all of these models have been 
shown to lead to varying degrees of increased TEER. However, while TEER has 
increased, only small changes in marker paracellular permeability were seen and still 
represent a drastically less restrictive model in comparison to in vivo conditions.34 An 
additional downside to these models is in increased complexity in cell culture which may 
hinder their utility in high-throughput screens.  This is especially true of the models 
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which utilize culturing cells on the underside of the Transwell® support.  In order to 
culture in this fashion, the filter is first flipped and cells are allowed to adhere and 
proliferate for a designated amount of time.62  This process is likely to be a very difficult 
accomplishment by automated high-throughput cell culture technologies.  
 Due to the continued lack of adequate tight junctions in the Transwell® model, a 
few new models have been developed.  One of these models was coined the dynamic in 
vitro model.66  Here a hollow porous fiber is used instead of a flat filter.  Endothelial cells 
are seeded onto the inside of this fiber and in some cases supporting cells are seeded onto 
the outside.  After adhesion, media is pumped through the model which allows for 
continual shear on the cells similar to that found in vivo.67  Interestingly, while further 
investigation is needed, hCMEC/D3 TEER approaches 1000 Ω*cm2 suggesting that shear 
may play a crucial role in BMEC differentiation.68  Additionally, new microfluidic 
models have been established which also utilize shear as a mechanism of 
differentiation.69  In these models, a semi-porous filter is placed between two 
microfluidic channels.  The setup of these models is very similar to the Transwell® 
models, with the exception that media is then pumped across these channels to mimic 
shear.  Due to the small size of these models, they also require a much lower number of 
cells, which may allow them to be conducive to studies with primary human cells.69  
Although it is an interesting model, at this time TEER values in these microfluidic 
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CHAPTER 2. INNOVATION AND OPTIMIZATION OF A DIRECT 
CONTACT BLOOD-BRAIN BARRIER IN VITRO MODEL 
2.1 Innovation of a Direct Contact Coculture In Vitro Model  
Cell Selection 
 Cell selection first began with selection of an endothelial cell line.  While it is 
believed that primary human BMEC’s may represent the most physiologically relevant 
cell line for the model, at this time they are cost prohibitive due to their low supply and 
high demand.  Therefore, an immortalized human BMEC line was selected.1 Because of 
its history in our lab and popularity in the field, the human cerebral microvessel 
endothelial cell line (hCMEC/D3) was selected as the endothelial cell line for initial 
studies.  
The hCMEC/D3 cell line was developed and graciously donated by Dr. Pierre 
Couraud of the Universite Rene Descartes.  The primary cell line was isolated from 
excised tissue of an adult female with epilepsy and then immortalized through lentiviral 
transduction of hTERT and SV40 large T-antigen.2  These proteins act in conjunction to 
prevent reduction in telomere length which acts to extend the useful number of passages 
for a cell line. The hCMEC/D3s are known to grow for at least 35 passages without 
exhibiting dedifferentiation or senescence, which represents a large increase in useful 
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lifespan over primary cells which often last less than 5 passages.3 In addition, 
hCMEC/D3 cells are contact-inhibited meaning that upon cell-cell contact the cells move 
from a proliferative state to a differentiated state. This makes them a good candidate for 
monolayer formation in in vitro studies.2,3 
In addition, the cell line also expresses most BBB-specific markers which are 
important in cell screening of pharmaceutical compounds across the BBB.3  hCMEC/D3s 
express tight junction proteins such as ZO-1, JAM-A, occludin, as well as claudins, 
including claudin-5 which is thought to be the most important for BBB tightness.4  They 
are also known to express a number of efflux proteins including P-glycoprotein, MRP1, 
and BCRP.5  Finally, previous work in our lab has shown expression of a number of ABC 
and SLC transporters.6  However, while all of these proteins are expressed, their 
expression in hCMEC/D3s varies widely when compared to primary human BMECs.7  In 
addition, at least when grown in monoculture, localization at cell-cell contacts of some 
tight junction proteins is not seen which may indicate the reason for increased 
paracellular permeation across hCMEC/D3 monolayers. 
Due to the current lack of an established immortalized human astrocyte cell line, 
primary human astrocytes were purchased from ScienCell.  While a lack of supply and 
high cost are disadvantages to using the primary human astrocytes, the use of a human 
cell line was deemed necessary leaving few options at this time.  In addition, it’s 
speculated that lot-to-lot differences in astrocytes would have reduced effects when 
compared to endothelial cells due to their mostly supportive role in barrier formation.  
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This is confirmed in part by insignificant differences between multiple cell lots currently 
used in the lab. 
 
Direct Contact Model 
 In order to initially test the hypothesis that direct-contact coculture of hCMEC/D3 
and human astrocytes leads to a more physiologically relevant model, a preliminary study 
was run to measure the differences in [C14]-Mannitol permeability between hCMEC/D3 
cells alone in monoculture and in coculture with human astrocytes.  Initial studies were 
conducted on collagen coated Transwell® filter supports.  In order to maintain 
physiological relevance, the human astrocytes were plated first at 40,000 cells/cm2 in 
astrocyte medium. Astrocytes were allowed to proliferate to confluence which took 
approximately two days.  A confluent layer of astrocytes was used to allow maximum 
contact between human astrocytes and hCMEC/D3s as well as to allow the hCMEC/D3s 
to have an increased chance of forming their own confluent monolayer on a more even 
surface.  In addition, this time allows the astrocytes to produce their ECM which is 
thought to enhance BBB differentiation.  After human astrocytes reached confluence, 
hCMEC/D3 cells were plated in supplemented EBM-2 at a density of 100,000 cells/cm2.  
This density, up to two-fold higher than normally used, was selected as 100% attachment 
to the astrocyte monolayer wasn’t expected.  The hCMECs were then allowed 7 days to 
proliferate and differentiate in contact with the human astrocytes before [C14]-Mannitol 
permeability was measured.  The hCMEC/D3 monocultures were grown in a similar 
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fashion, onto collagen-coated Transwells® at a density of 100,000 cells/cm2 and allowed 
to grow for 7 days before studies.  The results of the initial study are shown below. 
 
 
Figure 2.1.  Effect of Direct Astrocyte Coculture on hCMEC/D3 [C14]-Mannitol 
Permeability. Data is means ± 1 standard deviation of N=3 studies. **:p<0.05 
 
 As can be seen, a significant reduction in [C14]-Mannitol, a paracellular marker, 
was measured when growing hCMEC/D3 cells in coculture with human astrocytes versus 
monoculture.  Given that one of the significant limitations of hCMEC/D3 monolayers lies 































direct-contact coculture may serve as a more physiologically-relevant model for in vitro 
BBB permeability prediction. 
 
2.2 Optimization 
 While initial studies were promising, additional optimization was conducted.  
Optimization of in vitro models is often extensive as many factors play a role in protein 
expression and cell function.  While not an exhaustive optimization, the following studies 
elucidate parameters that may have the most influence.  Since the greatest drawback to 
the hCMEC/D3 cell line is its high paracellular permeability, optimization was focused 
on reducing permeability of the paracellular markers [C-14]-Mannitol and [C14]-Sucrose. 
 
Seeding Density 
 Seeding density represents the number of cells per area plated on the Transwell® 
permeable support and is given in the units of cells/cm2.  Seeding density serves as an 
important parameter, especially for contact inhibited cell lines like the hCMEC/D3s.  
Overseeding at a high density can lead to overgrowth, monolayer doming, and multi-
layer formation which reduce the formation of tight junctions.  On the other hand, 
underseeding contact-inhibited cells can lead to colony-like growth due to high amounts 
of localized cell-cell contact before confluence is reached.  A broad range of densities for 
both hCMEC/D3s (50-100,000 cells/cm2) and human astrocytes (10-40,000 cells/cm2) 




Figure 2.2.  Effect of Human Astrocyte and hCMEC/D3 Cell Densities on [C14]-
Mannitol Permeability. Key is represented as hCMEC/D3 density x1000 followed by 
human astrocyte density x1000). Data is means ± 1 standard deviation of N=3 studies.  
 
As can be seen, initial studies suggest that at least in monoculture, higher 
hCMEC/D3 cell densities lead to lower permeability. It should be noted that 250,000 
cells/cm2 was also run, however, the cell monolayers began to roll making them unable to 
be used for permeability testing.  Interestingly, however, at least in the large range of 
densities measured, neither the hCMEC/D3 or human astrocyte density seems to play a 
significant role under current culturing conditions. In addition, no trends were seen that 









































 In this case, seeding time represents the number of days the cells are allowed to 
grow post-hCMEC/D3 seeding.  Seeding time is often useful in determining both the 
optimal and acceptable range of days to conduct permeation studies.  If studies are done 
too quickly, the cells do not have adequate time to reach confluence, differentiate, and 
express tight junction proteins, efflux transporters, etc.  However, if the cells are grown 
for too long, the cells begin to go through apoptosis and monolayer integrity is lost.  
Also, these additional culture days represent an increase in both cost and time which 
hinder the utility of a model.  Previous work in our lab suggests that the best day for 
culturing hCMEC/D3 monocultures is approximately 14 days.  For this reason we chose 






Figure 2.3.  Effect of Seeding Time on [C14]-Mannitol Permeability. Data is means ± 1 
standard deviation of N=3 studies.  
 
 Interestingly, over the time course of the studies run from day 5-19, seeding time 
seemed to show little significance on [C14]-Mannitol permeability.  The highest 
permeability was on day 5, which suggests that full confluence and differentiation still 
isn’t reached at this time.  However, neither significant differences nor trends were seen 
from day 7 to day 19.  This suggests that the hCMEC/D3 monolayers reach full 
confluence and tight junction differentiation by day 7 and are viable at least until day 19.  
While for our purposes day 7 appears to be the best day for studies in terms of cost, time, 
and money, it should be noted that only paracellular permeability has been measured at 
this time.  Additional culture time may be required for full differentiation and 
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physiologically relevant protein expression and function.  Further studies need to be 
conducted to elucidate these changes in protein expression over time, however, these 
studies are currently cost-prohibitive. 
 
Seeding Order 
 In order to determine if a confluent astrocyte monolayer was necessary for 
hCMEC/D3 monolayer formation, both hCMEC/D3 cells and human astrocytes were 
plated concurrently.  In these studies, hCMEC/D3s and human astrocytes were plated 
together at 100,000 and 40,000 cells/cm2 together on collagen coated Transwells® and 
compared to studies conducted as described in section 2.1.2. Results of the study are 
shown below. 
 
Figure 2.4.  Effect of Concurrent Plating on  [C14]-Mannitol and [C14]-Sucrose 

































As expected, it is apparent from this study that concurrent plating of human 
astrocytes and hCMEC/D3’s significantly disrupts the ability of the hCMEC/D3s to form 
a monolayer and establish cellular tight junctions.  This is likely due to a purely physical 
or steric interaction with the human astrocytes blocking the ability of neighboring 
hCMEC/D3 cells to establish cell-cell contact.  While concurrent plating doesn’t appear 
to be ideal, additional studies could be conducted to establish the optimal of time to seed 
hCMEC/D3 cells after human astrocyte plating.  
  
Basement Membrane Selection 
 The basement membrane protein(s) used in a cell culture system are often used as 
a means to keep a cell monolayer flat for in vitro studies.  Frequently, endothelial cells 
will roll into a capillary-like formation upon differentiation due to the poor adhesion 
between endothelial cells and cell culture plastics.  This prevents their use in Transwell® 
based permeability studies due to the lack of a monolayer and a defined direction of 
membrane polarization.  To counteract this, a basement membrane protein is first seeded 
down onto the Transwell® and given time to adhere to the plastic.  After which, the cell 
line is placed onto of this ECM layer which acts as a “glue” between the cell line and the 
plastic. 
 However, while the basement membrane protein is often chosen solely on its 
ability to stabilize a cell monolayer, it is known that the ECM is important for cell 
proliferation and differentiation.8  Therefore, four different membrane proteins were 
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tested including Type I rat tail collagen, poly-L-lysine, fibronectin, and MaxGel to 
measure their influence on tight junction formation.  It should be noted that in vivo some 
of the basement membrane proteins tested are found at low or zero levels.  Consequently, 
MaxGel, a proprietary ECM made by Sigma-Aldrich, was also selected as a more 
relevant matrix.  MaxGel contains a mixture of basement membrane proteins including 
collagens, laminin, fibronectin, tenascin, elastin, proteoglycans, and glycoaminoglycans.  
Due to the complex nature and closer composition to that found in vivo, MaxGel is often 
used to help promote proliferation and differentiation in BBB cell lines. 
 
Figure 2.5.  Effect of Basement Membrane Protein Selection on  [C14]-Mannitol 
Permeability. Data is means ± 1 standard deviation of N=3 studies.  
 
 While fibronectin was found to give a significantly higher permeability for [C14]-




























differences.  However, seeding onto poly-L-lysine and Maxgel led to quantitatively 
slower paracellular permeability.  Due the high cost of MaxGel, and the difficulty in 
working with it, poly-L-lysine was selected as the best choice for future studies. One may 
question why such small changes were seen upon using different basement membrane 
proteins, particularly in the case of MaxGel.  It is hypothesized that this is due to the 
nature of the direct coculture model.  In this case, human astrocytes are plated onto the 
basement membrane protein and then allowed to produce their own ECM in which the 
hCMEC/D3 cells can adhere.  As the hCMEC/D3 cells are the rate-limiting barrier in 
paracellular permeation across the coculture model, a large change would only be 
expected if the modification in basement membrane proteins caused an alteration in 
astrocyte secretion of a matrix protein involved in BMEC differentiation. 
 
Media Selection 
 Due to the nature of the direct contact coculture model containing two cell lines, it 
is possible that differentiation and proliferation may occur better in one media over 
another.  The hCMEC/D3 cell line is grown in an endothelial basal medium (EBM-2) 
base from Lonza Inc., while the human astrocytes are grown in a proprietary human 
astrocyte medium (AM) sold with the primary cells by ScienCell.  In practice, both cell 
lines grow in both mediums, but in monoculture grow best in their perspective mediums.  
For this reason, all coculture studies began with plating, proliferation, and differentiation 
of astrocytes in astrocyte media for the first two days prior to hCMEC/D3 plating.  
Following hCMEC/D3 plating, the cells were then either kept in astrocyte media for the 
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remaining seven days or switched over to EBM-2 for the remaining seven days.  In 
addition, due to the nature of the Transwell®, it is also possible to add separate mediums 
in the apical and basolateral compartment. This allowed for the investigation of EBM-2 
on the apical side in contact with the hCMEC/D3 cells and astrocyte medium in the 
basolateral side in closer contact to the human astrocytes. 
 
 
Figure 2.6.  Effect of Base Medium on [C14]-Mannitol Permeability Across the Direct 
Contact Coculture Model. Data is means ± 1 standard deviation of N=3 studies. *: 
p<0.05 **:p<0.01 
 
 Figure 2.6 shows that the coculture model grown with EBM-2 in both 
compartments leads to the lowest paracellular permeation of [C14]-Mannitol.  The 






























basolateral compartment was significantly less restrictive than EBM-2 in both 
compartments, however, both were much tighter than the coculture grown in just 
astrocyte medium.  This isn’t unexpected as the hCMEC/D3 cell line is the rate limiting 
barrier in the model and grows best in EBM-2. In addition, the majority of the 
proliferation and differentiation of the human astrocytes is likely completed by the time 
the media is switched to EBM-2.  Further investigation would need to be completed to 
elucidate the mechanism behind the differences between hCMEC/D3 differentiation in 
EBM-2 vs. astrocyte medium, however, due to the proprietary formulas of each medium 
investigation would be difficult. 
 
Media Optimization 
 While EBM-2 in both the apical and basolateral compartments of the coculture 
model was found to elicit the tightest paracellular barrier, further media modifications 
may lead to further tightening.  Previous unpublished work in our lab has shown that for 
hCMEC/D3 monolayers, addition of different soluble factors, including growth factors, 
metal ions, antioxidants, lipids, and buffers, leads to significant tightening.  As the direct 
mechanisms behind hCMEC/D3 monolayer tightening upon coculture with astrocytes are 
unknown, further investigation was done to elucidate the effects of media modification 






 Serum is often used in cell culture as it contains a number of factors important for 
cell growth and proliferation.9 Its use is often needed not only for initial growth, but also 
to prevent senescence or apoptosis even after differentiation of some cell lines.  However, 
studies using primary porcine BMECs have found that removal of serum during cell 
culture led to a two-fold increase in transendothelial electrical resistance (TEER) which is 
often indicative of a restriction in paracellular flux.10 In addition, cells exhibited 
increased localization of ZO-1, occluding, and claudin-5 to cell-cell junctions and a 
flatter morphology.11  In order to test these conditions, the direct contact coculture system 
was grown in serum for the first two days of culture to allow for proliferation and 
confluence.  After two days, serum-free media was added and compared to cell cultures 
grown with serum for the extent of the study.  To measure changes in paracellular 




Figure 2.7.  Effect of Serum-Free Differentiation Conditions on [C14]-Mannitol 
Permeability Across the Direct Contact Coculture Model. Data is means ± 1 standard 
deviation of N=3 studies. *: p<0.05  
 
Figure 2.7, indicates that in both cases, media containing serum for the extent of 
the study provided a tighter monolayer.  This may indicate that extended time without the 
presence of serum caused hCMEC/D3 dedifferentiation and loss of some tight junction 
structure or function.  It should be noted that the cells used in the studies above utilized 
primary porcine BMECs which may be less susceptible to dedifferentiation in serum-free 


































measure the effects removing serum later in culture and of reduced-serum conditions as 
opposed to serum-free conditions. 
 
Hydrocortisone 
 Hydrocortisone is an endogenous anti-inflammatory glucocorticoid hormone 
which acts through inhibition of pro-inflammatory factors such as tumor-necrosis-factor 
alpha (TNF-alpha).  In vitro studies have shown that TNF-alpha signaling is responsible 
for tight junction breakdown and increased paracellular permeability.12  While TNF-alpha 
mRNA is not found in hCMEC/D3 lysates, it is possible that it may be produced by the 
human astrocytes or found in the fetal bovine serum added to cell culture medium. To 
counteract the possible effects of TNF-alpha from cell culture media, previous studies 
were completed to examine the effects of adding 50 nM hydrocortisone to cell culture 
media which resulted in substantial decreases in paracellular permeability and increases 
in claudin-1, claudin-5, occludin, and VE-cadherin.12 Furthermore, previous unpublished 
work in the Couraud lab suggests that an increased amount of hydrocortisone (1.4 μM) 
provides additional monolayer tightening.  However, due to the increased complexity 
with the coculture, similar studies were conducted with 1.4 μM or 100 nM 
hydrocortisone added at the start of hCMEC/D3 culture, or after two days of 
proliferation.  These two days were given to allow the hCMEC/D3 cells to first 




Figure 2.8.  Effect of Hydrocortisone Concentration and Time of Addition on [C14]-
Mannitol Permeability. Here, 1.4 μM at the Start Represents Control Conditions. Data is 
means ± 1 standard deviation of N=3 studies. *: p<0.05  
 
 Results in Figure 2.8 suggest that a larger hydrocortisone from the beginning of 
cell culture represent the lowest [C-14]-Mannitol permeability.  Interestingly, for lower 
hydrocortisone levels, a substantial decrease in permeability was seen when 
supplementing media after two days.  Additional studies may be conducted to analyze 



































 While sodium bicarbonate is the most common buffer used in cell culture, a 
number of organic buffers are also used.13  Sodium bicarbonate is often used due to its 
low cost and ability to buffer around physiological pH in 37oC, 95% relative humidity, 
and 5% CO2 conditions used in cell culture incubators.  However, due to the chemical 
nature of the sodium bicarbonate, if excess CO2 is not provided, it is released into the 
atmosphere leading to high alkalinity up to pH 8.5.  This could be problematic for 
hCMEC/D3 cell culture as these cells are known to be susceptible to even relatively small 
pH changes.14  In an attempt to counteract this, an organic buffer, HEPES, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, was selected to buffer EBM-2 medium.  
HEPES has a pH of approximately 7.4 at 37oC making it a good choice for 
physiologically-relevant BMEC growth.  Yet, HEPES is not without its own drawbacks.  
In in vitro cultures of some cell lines, HEPES is known to reduce the uptake of amino 
acids by glial cells.15 As the human astrocytes are a glial cell line, it is possible that 
HEPES may be detrimental to the coculture model.  In order to analyze possible toxicities 
with the coculture, a broad range of HEPES concentrations from (10-50 mM) were tested 







Figure 2.9.  Effect of HEPES Buffer Concentration on [C14]-Mannitol Permeability. 
Data is means ± 1 standard deviation of N=3 studies. *: p<0.05. Note: All Coculture 
Permeabilities are Significantly Lower (p<0.05) than hCMEC/D3 Permeabilities at the 
same HEPES Concentration. Significance in the Figure is Represented as a Significant 
Decrease over Control (10mM) HEPES Concentration for Coculture Data. 
 
 Interestingly, while the coculture was found to still be significantly less permeable 
than hCMEC/D3 monolayers at all HEPES concentrations, higher HEPES concentrations 
led to quantitatively lower [C14]-Mannitol permeability.  However, it does appear that 
some toxicities may be evident at 50 mM HEPES due to a non-significant increase over 
25mM.  As manufacturer-reported toxicities are usually found between 40 and 50 mM, 
our findings correlate with literature. While HEPES appears to provide non-toxic 




























mechanistic pathway leading to the significant tightening found when increasing HEPES 
buffer from 10 mM to 25 mM.  This may be due to the increase in buffer capacity, or 
small change in pH caused by increasing buffer concentration.16  However, some 
literature suggests that HEPES may play a role in increasing ATP concentrations in 
vitro.15  This increased ATP may possibly lead to a cascade of events leading to increased 
tight junction protein expression or localization. 
 
Lithium Chloride 
 Studies in animal primary endothelial cells suggest that activation of the Wnt/β-
catenin pathway leads to increased expression of claudin and other tight junction proteins 
by BMECs.17 While both expression and localization are necessary in tight junction 
formation, an increased expression of claudins, especially claudin-5, which is thought to 
be one of the main BBB phenotypic proteins, may lead to an increase in tight junction 
formation and decreased paracellular flux.  A number of proprietary molecules are 
available to upregulate the Wnt/β-catenin pathway, however, lithium chloride (LiCl), a 
relatively cheap and obtainable compound is also known to stimulate this pathway 
through inhibition of β-catenin phosphorylation and eventual degradation.18  In fact, 
previous work on hCMEC/D3 monolayers has shown that 10 mM LiCl supplementation 
led to 2-3 fold increases in claudin-3 and -5 expression and approximately 20% reduction 
in Lucifer Yellow, a fluorescent paracellular marker, permeation.17  In order to test this 
hypothesis, 10 mM LiCl was added to EBM-2 at the start of hCMEC/D3 culture or two-
days after.  These two days were given to allow the hCMEC/D3 cells to proliferate and 
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become confluent as LiCl is also known to promote differentiation.  Premature 
differentiation before reaching confluence may lead to incomplete monolayer formation 
as little proliferation occurs after differentiation. Results of the study are shown below. 
 
 
Figure 2.10.  Effect of 10mM Lithium Chloride on [C14]-Mannitol Permeability. Control 
Conditions are Grown Without Lithium Chloride. Data is means ± 1 standard deviation 
of N=3 studies. *: p<0.05  
 
 While literature suggests increased tight junction protein expression and reduced 
paracellular flux in hCMEC/D3 monocultures, similar results were not seen in coculture 
under the conditions tested.  In fact, significantly increased paracellular permeability was 
seen for cultures containing LiCl.  However, as noted above, LiCl is known to promote 
differentiation.  It is possible that two days was not enough time for full hCMEC/D3 
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confluence to be reached in coculture.  This idea is upheld by a quantitative, though non-
significant, decrease in permeability when adding LiCl on day 2 as well as Figure 2.3 
which shows increased permeability of cocultures until day 5.  
 
Calcium 
 Some investigation in our lab has led to the finding that the EBM-2 media, 
manufactured by Lonza, contains a minimal amount of calcium (Stephen Carl Thesis, 
2009).  While the mechanism is not well understood, extracellular calcium concentration 
is known to play a role in tight junction function.  This was shown through addition of 
EGTA and other calcium chelators which lead to the opening of tight junctions and large 
increases in paracellular permeability.19  That being said, previous unpublished studies in 
our lab have shown that adding excess calcium to EBM-2 media led to insignificant 
changes in [C14]-Mannitol permeability across hCMEC/D3 monolayers.  However, to 
ensure low calcium levels aren’t responsible for high paracellular permeability in the 
coculture model, 1mM calcium was added in excess and [C-14]-Mannitol and [C14]-




Figure 2.11.  Apparent Permeability of [C14]-Mannitol and [C14]-Sucrose in Normal 
EBM-2 (Control) and EBM-2 with 1 mM Excess Calcium Ion. Data is means ± 1 
standard deviation of N=3 studies.**: p<0.01 
 
 Similar to previous hCMEC/D3 monoculture studies in our lab, Figure 2.11 
shows insignificant changes in coculture [C14]-Mannitol permeability.  In fact, for both 
[C14]-Mannitol and [C14]-Sucrose excess calcium led to increased paracellular 
permeability. Interestingly, significant changes were seen for [C14]-Sucrose, however, it 
should be noted that this significance is in most part due to unusually small deviations.  
While this study suggests that excess calcium may actually impair tight junction function 
in our model, it should be noted that only a single excess calcium concentration was 


































Functional Drug Efflux 
 The optimization studies above, as well as previous media optimization by our lab 
and other labs using the hCMEC/D3 cell line have mostly focused reduction in 
paracellular permeability.  While the exclusion of small hydrophilic molecules from 
moving through paracellular tight junctions is one of the BBB’s main barriers to drug 
delivery, efflux of hydrophobic molecules, preventing transcellular permeation, also 
represents a significant barrier. Therefore, it is important to also measure changes in 
functional hCMEC/D3 efflux when cocultured in direct contact with human astrocytes.  
In order to assess functional efflux, two types of studies are common.  The first is the 
measurement of the directional permeability in both the apical-to-basolateral (AB) and 
basolateral-to-apical (BA) directions.  Due to the unidirectional efflux back into the 
apical compartment, an efflux substrate should have increased permeation in the 
basolateral-to-apical direction and reduced permeation in the apical-to-basolateral 
direction.  Therefore an AB/BA ratio greater than 2.5 or 3 is often believed to represent 
the presence of drug efflux transporters. Additionally, efflux activity can be estimated 
through uptake experiments.  In this case, cells are seeded onto culture well plates instead 
of Transwell® supports and the rate of cell uptake is measured over a defined time.  In 
this case decreases in the rate of uptake suggest increased efflux activity.  These studies 
are especially useful when trying to optimize conditions due to the low cost of well-plates 
in comparison to Transwell® supports. 
 In order to examine efflux of the direct contact coculture model in comparison to 
hCMEC/D3 monocultures the bidirectional permeability of 1μM [C14]-Verapamil was 
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measured and can be seen in Figure 2.12.  No change was seen in either direction when 
comparing the mono- and cocultures.  In addition, there were no significant differences in 
AB or BA directional permeability in either model suggesting no functional efflux.  This 
is interesting as numerous previous reports, including those in our own lab, have shown 
the functional presence of p-glycoprotein including bidirectional studies, uptake studies, 
and localization by microscopy.4,6,20-22  However, upon further investigation, it was found 
that Verapamil is both a P-gp substrate as well as an inhibitor (though we are 
approximately 10-fold below reported Ki values) which may confound results. 
 
 
Figure 2.12.  Apparent Permeability of [C14]-Verapamil in Apical-to-Basolateral and 
Basolateral-to-Apical Directions for hCMEC/D3 and Coculture Models. Data is means ± 






























  As Verapamil was found to potentially be a conflicting substrate, further 
investigation was done using [C14]-Paclitaxel.  Additionally focus was moved to first 
quantifying function efflux in the direct coculture system due to costs associated with the 
studies.  Paclitaxel studies were run at 10 μM concentration in a similar fashion; 
however, in this case bidirectional permeability was also measured in the presence of a p-
glycoprotein inhibitor, 5 μM Cyclosporine A (CsA).    Again, no significant differences 
were seen between AB and BA permeability coefficients in Figure 2.13.  CsA did lead to 
a small increase in AB permeation, which may signify some inhibition, however, this is 
complicated by a concurrent increase in BA permeability. 
 
 
Figure 2.13.  Apparent Permeability of [C14]-Paclitaxel in Apical-to-Basolateral and 
Basolateral-to-Apical Directions for Coculture Models with and without Cyclosporin A 





























 This data seems to support, the conclusions found with Verapamil, however, to be 
confident a final study was done measuring the bidirectional permeability of 5 μM 
Rhodamine-123 (R123) with inhibition by 20 μM Verapamil.  As noted above, while 
Verapamil is a p-glycoprotein substrate, it also acts as an inhibitor at concentrations 
above ~10 μM.23  Results in Figure 2.14 are slightly more encouraging as R123 showed 
nearly significant (p=.058) increases in BA permeability over BA.  In addition, these 
differences disappeared in the presence of an inhibitor with a reduction in BA 
permeability and an increase in AB.  That being said, the BA/AB ratio is still well under 
2 which suggests that even if functional efflux is present it is at a low level. 
 
 
Figure 2.14.  Apparent Permeability of Rhodamine-123 in Apical-to-Basolateral and 
Basolateral-to-Apical Directions for Coculture Models with and without Verapamil 





























 These studies all appear to contradict the results found by others who have shown 
active efflux expression and function in the hCMEC/D3 model.  At least in the case of 
our lab’s hCMEC/D3 cells, functional expression of efflux proteins has been reduced or 
lost completely.  One speculation of why this may be is the high passage number used in 
these studies.  Studies were conducted around passage 45, and recent research suggests 
that P-gp expression may be reduced after passage 40.22  However, even at the reduced 
levels shown at higher passage numbers, the expression found was still relatively high.  
In order to test this hypothesis, cells of lower passage number have been purchased and 
will be tested in the future. Another possibility is a lack of polarized efflux expression in 
our model.  In this scenario, efflux would occur in both directions and any changes in AB 
and BA permeability would be equivalent.  One method to test this hypothesis would be 
cellular uptake as even unpolarized expression will limit uptake into the cell.  However, it 
is possible that uptake by astrocytes in the coculture model could make delineation of 
hCMEC/D3 uptake difficult.  Finally, through discussion with others working with the 
cell line, this problem does not seem to be solely ours.  While not discussed in the 
literature, it appears that this cell line has the tendency to gain and lose efflux expression 
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CHAPTER 3. DEVELOPMENT OF A PHYSIOLOGICALLY 
RELEVANT BLOOD-BRAIN BARRIER COCULTURE MODEL 
 
Modified From: Kulczar C, Lubin KE, Ngendahimana A, Lefebvre S, Miller DW, Knipp 
GT. Development of a Direct Contact Astrocyte-hCMEC/D3 Blood-Brain Barrier 
Coculture Model. (In Submission) 
 
3.1. Introduction 
The blood-brain barrier (BBB) is a highly restrictive barrier between the systemic 
circulation and the brain parenchyma.1-5 The BBB functions to exclude harmful 
xenobiotics while permitting the entry of nutrients and removal of waste allowing for a 
neuronal environment optimal for development and function.6-8  One of the key elements 
of the BBB is a continuous endothelium with the presence of exceedingly restrictive tight 
junctions between brain microvessel endothelial cells.  These tight junctions prevent the 
paracellular movement of hydrophilic molecules and ions to a greater extent than 
anywhere else in the body.9,10  This tightness is believed to be due, in part, to an increased 
expression of claudin-3, 5, and 12 in brain microvessel endothelial cells compared to 
microvessel endothelial cells in the periphery.11 In addition to tight junctions, BBB 
endothelial cells also express a number of drug metabolizing enzymes, such as 
cytochrome P450 enzymes (CYP450), and efflux transporters, such as P-glycoprotein (P-
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gp) and breast cancer resistance protein (BCRP), which act to efflux xenobiotics moving 
transcellularly.12-14 
Further investigation of the BBB reveals supporting cells, such as astrocytes and 
pericytes, form a symbiotic, synergistic relationship with BMECs that significantly 
enhances the barrier properties.3,15,16  Due to their close-knit interactions leading to BBB 
formation, the collection of endothelial cells, astrocytes, and pericytes was coined the 
neurovascular unit.  Each of the cells play a role in creation of the barrier, and while tight 
junctions between the endothelial cells are responsible for the barrier function itself, the 
astrocytes and pericytes are thought to be necessary for co-differentiation with the 
endothelial cells.17 Among other things, astrocytes are believed to be responsible for 
regulating development of tight junctions, the movement of water and glucose across the 
BBB, metabolism, and the localization of transporters.2  In addition, astrocytes highly 
express CYP450 enzymes and may serve an important neuroprotective role by 
metabolizing and removing many xenobiotics, including pharmaceutical compounds.18  
Pericytes on the other hand, are thought to be important for production of soluble growth 
factors as well as production and maintenance of an extracellular matrix rich in collagen, 
fibronectin, proteoglycans, and laminin that is important for integrity of the BBB and 
may be important for proper BBB differentiation.19-21 
Due to the increasing importance of translatable knowledge of the BBB and 
permeation across the barrier, a number of different in vitro models have been 
established.8,17,22-32  Many of these models utilize primary human or animal BMECs.33 
While primary human BMECs may provide the most ideal and relevant model, the 
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availability of such tissues is minimal, reducing their utility for high throughput 
screening.6  Due to the lack of human tissues, many attempts have been made to use 
animal tissues as a surrogate.  These cells are often of murine, bovine, or porcine origin.  
Primary cells of animal origin have been shown to provide relatively high 
transendothelial electrical resistance (TEER) indicative of the presence of developed tight 
junctions.25,29,31,34 However, one must question the physiological relevance of these 
models for drug screening, especially based on species differences including non-
paracellular routes of permeation indicative of the vast majority of BBB permeable 
compounds.  Therefore, new models have been established making use of immortalized 
human tissues which provide the relevance of a human cell line without the disadvantage 
of short supply. 
One of the most often used immortalized human BMEC cell lines is the human 
cerebral microvessel endothelial (hCMEC/D3) cell line.  The hCMEC/D3 cell line was 
established through hTERT and SV40 large T antigen immortalization of endothelial 
cells isolated from microvessels of a human temporal lobe.35 hCMEC/D3 cultures form 
monolayers on collagen-coated surfaces and are contact inhibited lending themselves to 
high throughput Transwell® permeation studies. Analysis of the cell line and has shown 
similarities in morphology and protein expression between hCMEC/D3s and primary 
human BMECs.  However, hCMEC/D3s do not appear to form tight junctions consistent 
with those found in vivo, reaching TEER values of only 30-50 Ω*cm2 compared to TEER 
values of over 1000 Ω*cm2 in vivo in the frog.8,32,35-37  These leaky tight junctions may 
allow paracellular movement of compounds that permeate by the transcellular route in 
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vivo, leading to irrelevant permeability values.  While optimization of culture conditions, 
e.g. media, density, cell source, etc., has led to modest increases in monoculture TEER, 
these values are still well below those seen in vivo.6,38 
Due to the leakiness of these monocultures, many groups have examined methods for 
reducing the paracellular permeability of these models.  One approach is to use astrocyte 
conditioned media.39  In these studies, soluble factors released by the astrocytes were able 
to interact with BMECs to create a more in vivo-like environment that lead to enhanced 
differentiation and reduced paracellular permeability.  However, for hCMEC/D3 cultures, 
non-significant changes were seen in TEER when using astrocyte conditioned media.27,35  
Instead, the most significant reductions in paracellular permeability were seen when 
astrocytes were grown on the basolateral side of the filter or on the plastic well surface in 
the same Transwell® as the hCMEC/D3s (Figure 3.1A).8,32  While a reduction in 
paracellular permeability of marker compounds and increases in TEER were seen for 
both of these conditions, greater changes were observed in cells grown on the basolateral 
side of the Transwell®.6  These models are likely more physiologically relevant due to the 
symbiotic signaling and differentiation that is able to occur when both cell types are 
grown in the same culture. In addition, the increased tightness seen when growing 
astrocytes on the basolateral side of the Transwell® may reflect a closer proximity of 
astrocytic-released factors to endothelial cells thus producing a greater response through 
reduced dilution 28  Moreover, it is thought that the model in which cells are grown on the 
bottom of the Transwell® permeable support may lead to tighter junctions due to the 
ability of the astrocytic endfeet to migrate through the pores of the filter and interact with 
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the BMECs through direct contact. However, it should be noted, that migration through 
Transwell® supports, especially through 0.4μm pores which best support endothelial cell 
culture, is infrequent.34,40 
It is apparent from the studies mentioned above and analysis of the neurovascular 
unit, that the interplay between BMECs and astrocytes may serve an important role in 
differentiation of BMECs into providing a BBB phenotype.  In addition, these studies 
have shown the proximity of astrocytes and BMEC may be crucial.2,28,40  However, the 
methods described in previous coculture models entails separating BMECs and astrocytes 
by a filter support. While the Transwell® support is often depicted to be thin in cartoon 
representations, the support is approximately 10μm thick and may represent a significant 
barrier to cell-cell interactions. It is hypothesized that removing this obstruction and 
allowing direct cell-cell contact may allow further symbiotic signaling and differentiation 
to occur, which in turn may lead to further reduction in paracellular permeability and a 
more in vivo relevant model.  An illustration of the model is shown in Figure 3.1B. To 
our knowledge, this is the first study that provides evidence that direct contact may 















Figure 3.1. Past (indirect) vs. current direct contact coculture models.  A, previous direct 
contact coculture model with BMEC and astrocytes separated by Transwell® permeable 
filter support.  B, current direct contact coculture model, with BMEC and astrocytes in 





3.2 Materials and Methods 
 
Materials 
Trypsin, Phosphate Buffered Saline (PBS), Penicillin/Streptomycin, Type I Rat Tail 
Collagen, Poly-L-Lysine, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
Buffer, Fibronectin, MaxgelTM, Hank’s Balanced Salt Solution (HBSS), Hydrocortisone, 
human Basic Fibroblast Growth Factor (bFGF), Ascorbic Acid, and Fetal Bovine Serum 
(FBS) were acquired from Sigma-Aldrich Company (St. Louis, MO).  EBM-2 growth 
media was manufactured by Lonza Group (Walkersville, MD).  Lipid Concentrate was 
obtained from BD Biosciences (Sparks, MD).  0.4 μm Transwell® 12 well plates and T75 
flasks were made by Corning Lifesciences (Corning, NY).  Radiolabeled compounds 
were purchased from Moravek Biochemicals Inc. (Brea, CA).  The hCMEC/D3 cell line 
was graciously provided by Dr. Pierre Couraud of the Université Rene Descartes (Paris, 
France), while human astrocytes, Human Astrocyte Media, and Astrocyte Growth Factor 
were acquired from ScienCell Research Laboratories (Carlsbad, CA). 
Methods 
Cell Culture 
The hCMEC/D3 cells were cultured in EBM-2 supplemented with FBS, 
Penicillin/Streptomycin, bFGF, Hydrocortisone, Ascorbic Acid, Lipid Concentrate, and 
HEPES buffer. Cells were maintained in a 5% environment at 37oC.  HCMEC/D3 cells 
were passaged when confluence reached approximately 80%, at which time trypsinized 
cells were placed in a pre-collagenated (Type I) flask.  Media was changed every other 
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day. Human astrocytes were cultured under similar conditions in Human Astrocyte Media 
supplemented with FBS, Astrocyte Growth Factor, and Penicillin/Streptomycin.  Cells 
were passaged approximately every 5 days into flasks pre-coated with Poly-L-Lysine.   
 
Monoculture Studies 
In hCMEC/D3 monocultures, cells were seeded at a density of 1 x105 cells/cm2 on 
Corning Costar 12-well 0.4 μm polyester Transwells® pretreated with 65 μL of 1 mg/mL 
Type I rat tail collagen and allowed to grow for 7 days.  For human astrocyte 
monoculture, 4 x104 cells were seeded onto Transwells® coated with 2 μg/cm2 poly-L-
lysine and grown for 9 days prior to permeability studies. 
 
Indirect Coculture Studies 
Indirect coculture Transwells® were first pretreated with 65 μL of 1 mg/mL Type I rat 
tail collagen in ethanol in the apical chamber and left to evaporate for 4 hours.  Following 
evaporation, the Transwells® were flipped and 2 μg/cm2 poly-L-lysine was added to the 
basolateral side of the Transwells® and left overnight.  Human astrocytes were plated on 
the basolateral side of the flipped Transwells® at a density of 4 x104 cells/cm2 and left to 
attach for 4 hours. Transwells® were then placed into the normal orientation and grown 
for 48 hours.  After this time, hCMEC/D3 cells were plated in the apical compartment at 
a density of 1 x105 cells/cm2.  The coculture was left to proliferate/differentiate in EBM-2 
for an additional 7 days with media changes every other day before the permeability 




Direct Coculture Studies 
For direct coculture studies, Transwell® inserts were coated with 2 μg/cm2 poly-L-
lysine and left overnight.  Human astrocytes were then plated at a density of 4 x104 
cells/cm2.  Astrocytes were allowed to proliferate/differentiate for 48 hours in astrocyte 
media.  After 48 hours, media was removed and hCMEC/D3s were plated in EBM-2 at a 
density of 1 x105 cells/cm2. The coculture was grown in EBM-2 with media changes 
every other day for an additional 7 days before studies were conducted.  
 
Permeability Studies 
Permeability studies were performed at 37oC on a rocker plate in triplicate using 
[C14]-labeled markers ([C14]-Urea, [C14]-Mannitol, [C14]-Sucrose, [C14]-Inulin, 
[C14]-PEG-4000, and [C14]-Propranolol) at a concentration of 0.25 μCi/mL in HBSS. In 
all studies, human astrocytes ranged from passages 6-12 while hCMEC/D3 cells ranged 
from passage 36-48. Before all permeability studies, cells were washed twice with PBS 
before equilibrating in HBSS for 20 minutes shortly before the study.  100μL samples 
were taken at 15, 30, 45, 60, and 90 minute time points. 4mL of scintillation cocktail was 
added for analysis by scintillation counting. Permeability coefficients (cm/s) were 
obtained through the following equation: 
 
𝑃𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 =  
𝑑𝑀
𝑑𝑡






 is the rate of radionucleotide transfer across the cell layer, 𝐶0 is the initial donor 
concentration, 𝑆𝐴 is the surface area of the Transwell® filter support, and 60 represents a 
correction factor from minutes to seconds. 
 
Statistics 
Permeability studies were compared using a two-tailed unpaired student’s t-test with 




In order to delineate changes in BBB phenotype upon coculture with human 
astrocytes, permeability was measured with a number of marker compounds. However, 
the model was first optimized for minimal paracellular permeability. Extensive 
optimization of hCMEC/D3 and astrocyte seeding density, basement matrix, media, and 
seeding time were performed prior to the following studies (data not shown). The current 
method proved to be superior to other growth conditions investigated. 
 
Direct Contact Coculture 
As noted above, the hCMEC/D3 cell line, while tighter than other immortalized 
human BMEC cells, possess tight junctions that lack ideal physiological relevance. To 
investigate changes in tight junction pore radius, five marker compounds of varying 
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hydrodynamic radii were used to determine changes in paracellular permeability. As 
expected, increases in hydrodynamic radii lead to decreased apparent permeability 
coefficients for paracellular markers.  However, the extent of changes in permeability 
varied between mono- and coculture, likely due to the effects predicted by the Renkin 
molecular sieving function as the pore radii approaches the size of the sieved 
molecule.31,36,41,42 Although, it should be noted that in the presence of astrocytes the 
assumptions made by the Renkin function including the presence of a single pore, varied 
and increased tortuosity and porosity exists, thus the effects of permeation across the 
astrocytes cannot be easily corrected to obtain a pore radius.  
As shown in Figure 3.2, significant changes between the mono- and coculture were 
seen for [14C]-urea (2.96 ± 0.11 x10-5 cm/s and 2.43 ± 0.15 x10-5 cm/s; p=0.030), [14C]-
mannitol (1.98 ± 0.05 x10-5 cm/s and 1.52 ± 0.07 x10-5 cm/s; p=0.0004), [14C]-sucrose 
(1.52 ± 0.13 x10-5 cm/s and 1.17 ± 0.008 x10-5 cm/s; p=0.005), and [14C]-inulin (8.46 ± 
0.02 x10-6 cm/s and 7.55 ± 0.3 x10-6 cm/s; p=0.034) respectively.  Insignificant (p>0.05) 
changes were seen for [14C]-PEG-4000 (3.93 ± 0.36 x10-6 and 3.57 ± 0.10 x10-6 cm/s; 





Figure 3.2. Apparent permeability for 5 paracellular [14C]-labeled markers of various 
hydrodynamic radii. Studies were run in triplicate and subjected to student’s T-Test. 
Significant changes are noted with an asterisk (*) for p<0.05 and (**) for p<0.01. Error 
bars represent 1 standard deviation (n=3). 
 
Indirect Contact Coculture 
It is well established that changes in culture conditions and cell source can cause 
significant changes in protein expression of drug metabolizing enzymes, efflux proteins, 
etc,, which are the focus of ongoing studies.43,44 In addition, modifications in media have 
been shown to have considerable effects on BMEC differentiation and tight junction 
formation.32,45,46 To establish an internal lab control, an indirect coculture model was also 


































astrocytes in direct contact with hCMEC/D3 cells.  Figure 3.3 shows that direct contact 
leads to significant reduction in permeation compared to indirect contact of both [14C]-
mannitol (1.52 ± 0.07 x10-5 cm/s and 1.89 ± 0.15 x10-5 cm/s; p=0.038), and [14C]-sucrose 
(1.17 ± 0.008 x10-5 cm/s and 1.53 ± 0.12 x10-5 cm/s; p=0.035) respectively. 
 
 
Figure 3.3. Apparent permeability of [14C]-Mannitol and [14C]-Sucrose across direct and 
indirect contact cocultures. Studies were run in triplicate and subjected to student’s T-
Test. Significant changes are noted with an asterisk (*) for p<0.05 and (**) for p<0.01. 




























Direct Contact Indirect Contact 
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Passive Transcellular Permeability 
To investigate the effects on transcellular permeation when culturing human 
astrocytes and hCMEC/D3 cells in direct contact, [14C]-propranolol apparent 
permeability was measured.  Due to its high lipophilicity, the majority of propranolol is 
uncharged at physiological and a presumed minimal paracellular permeation it was 
selected as a marker for transcellular permeation.  Figure 3.4 shows that insignificant 
changes in [14C]-Propranolol apparent permeability were seen between hCMEC/D3 and 
direct contact coculture (1.91 ± 0.19 x10-5 cm/s and 1.61 ± 0.04 x10-5 cm/s; p=0.103). 
This may indicate transcellular permeation through hCMEC/D3 cells followed by passive 
transport across the human astrocyte layer which don’t possess tight junctions. However, 
these values are nearly 3-fold lower than astrocytes grown in monoculture (4.58 ± 0.41 
x10-5 cm/s). This makes it difficult to assess the effect of astrocytes on transcellular 




Figure 3.4. Apparent permeability of [14C]-Propranolol, a passive transcellular 
permeability marker. Non-significant changes (p<0.05) were seen between monoculture 
and coculture. Error bars represent 1 standard deviation (n=3). 
 
3.4 Discussion 
Previous research has demonstrated that the hCMEC/D3 cell line forms a barrier that 
is a functionally and physiologically relevant model for human BMECs.  This is 
predicated on the fact that hCMEC/D3 cells possess a similar morphology and protein 
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immortalized, of human origin, can be grown in monolayers, and is contact inhibited, 
properties which all lend themselves for use in in vitro permeability screening.32  
However, hCMEC/D3 monolayers lack the tightness found in vivo which may lead to 
increased paracellular permeation of drug molecules that in turn may obfuscate the ability 
to predict transcellular permeation that is observed when studying in vivo brain 
distribution.6 As has been previously shown, coculturing hCMEC/D3 cells with 
astrocytes has led to pronounced decreases in paracellular permeability for BMECs 
which may mitigate this problem.48  Moreover, the presence of the astrocytes enables a 
more relevant understanding of the transport across the in vivo neurovascular unit. 
 
Since the discovery of the neurovascular unit, this interplay between BMECs and 
astrocytes at the BBB has been studied. While there are still unknowns, a lot of their 
interactions have been elucidated.2,13,49,50  For BMECs, it has been shown that astrocytes 
play an important role in tight junction development, localization and expression of 
transporters, as well as upregulation of metabolic enzymes, which are currently being 
investigated.32,35,50 In addition, some of these interactions may require symbiotic crosstalk 
leading to co-differentiation17,51, and while some of these adaptations can be seen with an 
indirect coculture of BMECs with astrocytes in vitro; leakiness of the tight junctions is 
still significantly higher than in vivo conditions.6  It is hypothesized that one reason for 
continued leakiness is an inability for astrocytes to form true direct contact with the 
BMECs in this model due to the presence of the Transwell® permeable support.  This 
lack of contact may hinder cross-talk between endothelial cells and astrocytes.  For this 
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reason, a direct contact model with hCMEC/D3 cells seeded directly onto human 
astrocytes was investigated. 
 
Due to the importance of limiting paracellular permeation in in vitro BBB cell 
models, changes in permeation of five paracellular markers of various size; [14C]-urea, 
[14C]-mannitol, [14C]-sucrose, [14C]-PEG-4000, and [14C]-inulin were measured (Table 
3.1).  When comparing permeation through hCMEC/D3 monolayers to the coculture, all 
markers trended toward a reduction in paracellular permeation for the coculture.  For the 
largest marker, PEG-4000, results were insignificant (p>0.05), however, this isn’t 
unexpected as permeation through the hCMEC/D3 monolayer was sufficiently slow it is 
unlikely further pore size reduction would lead to sizable changes in permeability. A 
similar story can be said of the smallest marker, urea.  While significant reduction was 
seen (p<0.05), it is apparent that this model is still unable to prevent permeation of polar 
molecules in this very low molecular weight range.  The most significant changes were 










Table 3.1. Comparison of molecular weight and molecular radii with apparent 
permeability of paracellular model compounds. 
 
 
To investigate the impact of direct coculture, an indirect coculture with astrocytes on 
the basolateral side of the Transwell was also examined.  As mentioned, it is often 
difficult to compare models between different labs due to differences in culture protocol, 
media selection, passaging, and cell source.43,44  Therefore, the indirect model was 
established under the same conditions and protocols as the direct contact coculture. As 
was hypothesized, a significant decrease in [C14]-Sucrose apparent permeability was 
seen when the astrocytes were in direct cell contact. Further investigation is needed to 
determine the underlying factors leading to this increased tightness.  
 
To assess passive transcellular permeation the apparent permeability of [14C]-
propranolol was measured. Propranolol is often used as a passive transcellular marker 
due to its high octanol:water coefficient leading to almost exclusive transcellular 
permeation.52    Due to the extra cell layer in the coculture model, it was expected that 










Urea 60 1.7 1.8 2.43 ± 0.155 
Mannitol 182 3.6 4.3 1.52 ± 0.069 
Sucrose 342 4.6 5.2 1.17 ± 0.008 
Inulin 5000 13.9 10 0.754 ± 0.030 
PEG-4000 4000 16.4 15.9 0.357 ± 0.010 
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coculture, changes between mono- and coculture weren’t significant (p>0.05).  To further 
examine this discrepancy, [14C]-propranolol permeability was also measured across 
human astrocyte monolayers and was found to be approximately three-fold higher than 
hCMEC/D3 monolayers or the direct contact coculture.  This finding validates the 
coculture permeability data as the hCMEC/D3 cell layer appears to be the rate-limiting 
barrier to permeation. While astrocytes do play a role in our model, it is unknown if there 
is a significant contribution of paracellular flux for propranolol that may obfuscate 
transcellular permeation.  While propranolol is unlikely to cross the tight junctions 
between endothelial cells, astrocyte end feet are known to be much further apart with 
pores 20-30 Å wide which may allow greater paracellular movement.  Therefore, 
additional studies are required to understand differences between the apparent 
permeabilities for hCMEC/D3 and human astrocyte monocultures particularly to 
elucidate the mechanism of transport across the human astrocyte layer. 
 
Overall, this proof-of-concept study suggests direct contact coculture of human 
astrocytes and hCMEC/D3s leads to some tightening of the leaky tight junctions often 
found in hCMEC/D3 monoculture with minimal modification to other routes of 
permeation.  While this model is still significantly leakier than in vivo conditions it 
represents an improvement in the paracellular leakage observed in many cell culture 
models and an advancement in physiologically relevant screening models for determining 
passive diffusion properties of drugs in the BBB.  It should also be noted that while in 
vivo tightness would be ideal, it may be unnecessary for drug screening.  While current 
TEER values are much lower than found in vivo, it is possible that small changes in tight 
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junction pore radii will lead to very large increases in TEER.41 Due to the nature of 
paracellular permeation, these large changes in TEER may have little effect on 
paracellular permeation due to the difference in the hydrodynamic size of ions being 
measured (sodium, potassium, calcium, chloride, magnesium, etc vs. drug molecules).31,53 
That is, NCEs targeted to the brain are often much larger and more lipophillic molecules 
than the ions whose movement across the cellular barrier determine TEER.  In addition, 
the vast majority of all NCEs aren’t as small or polar as urea, mannitol, or even sucrose.  
TEER is also dramatically influenced by several other factors like ionic strength, buffers, 
and temperature that can be confounding variables.   
 
Lastly, species differences are a major cofounder in translation of preclinical 
screening to humans.  Differences in morphology, function, and regulation are all 
common.  Since the common goal is to expedite human translation, it may be better in 
theory to use a leaky human model than a tight animal model for the screening of 
pharmaceutical molecules, provided the human model can discriminate between 
compounds in series.  This will reduce some issues such transport and enzyme affinities 
and capacities observed between species and better enable an assessment of transcellular 
permeation in vivo in humans. 
 
3.5 Conclusion 
As the occurrence of neurological diseases rise along with the number of druggable 
targets and compounds, a more relevant and robust in vitro cell culture method has 
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become of paramount importance for preclinical screening and lead candidate selection 
and optimization.  The hCMEC/D3 cells have been shown to be functionally similar to 
primary brain endothelial cells, however, their main downfall has been the presence of 
leaky tight junctions. These leaky tight junctions obfuscate the delineation of transcellular 
routes of permeation of many compounds and potentially lead to inaccurate in vivo 
predictions.  Therefore, it is believed that reducing paracellular permeation to levels 
closer to that found in vivo may lead to a more robust BBB model.  
Some promise has been shown in the reduction of paracellular permeability through 
coculture with astrocytes.  However, current models often utilize indirect contact 
methods in which endothelial cells and astrocytes are separated by the Transwell® 
permeable support. Here it is shown that direct contact coculture of human astrocytes and 
hCMEC/D3 cells leads a significant decrease in permeation of paracellular markers.  This 
methodology may serve as a better model for further optimization and in vivo prediction. 
In addition, seeding of both cell types onto the apical chamber of the Transwell® is likely 
to be much more conducive to high-throughput screening.  Though, further investigation 
including microscopy, transcriptomic and proteomic analysis, and drug screening must be 
completed to confirm in vivo relevancy, it is believed that this model is a step in the right 
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CHAPTER 4. CYS34-PEGYLATED HUMAN SERUM ALBUMIN 
FOR DRUG BINDING AND DELIVERY 
 
Adapted With Permission from From: Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A. 
2015. Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery. 




 Protein function and recognition can be rationally modified by the covalent 
ligation of molecular structures such as optical tags1, targeting ligands2, carbohydrates3, 
and polymers.4,5 However, coupling methods that rely on available amines or carboxylic 
acids for amide bond formation typically have poor regioselectivity, and can result in 
intra- or intermolecular crosslinks that lead to protein denaturation, aggregation, or 
general loss of function.6 Site-specific ligation methods are highly desirable for 
introducing additional functionality to proteins without disrupting other physicochemical 
properties. A useful alternative to amide bond formation involves the chemoselective 
addition of alkylmaleimides to exposed cysteines.7 This method of conjugation has little 
to no effect on the electrostatic surface potential of proteins at physiological pH, and is 
thus less likely to induce unintended changes in secondary or tertiary structure.  N- and 
C-modified proteins have the intrinsic drawback of having different net charges relative 
92 
 
to the native protein, which can affect their conformational behavior, dispersion stability, 
aggregation kinetics, biomolecular recognition, and catalytic activity.6,8,9 
 PEGylation (i.e. the ligation of one or more polyethylene glycol chains to external 
residues) is a widely used tactic to modify the pharmacokinetic properties of drug 
carriers10,11 and protein-based biologics.12,13 Covalently attached PEG chains can stabilize 
proteins by providing a surrogate hydration shell,14 or prevent denaturation by limiting 
conformational freedom.15 While much attention has been paid to antibodies and other 
"functional" biomolecules, passive proteins such as human serum albumin (HSA) are also 
important candidates because of their putative roles in drug solubilization and delivery. 
HSA's native role as a plasma carrier makes it an ideal candidate for transporting 
hydrophobic drugs that possess higher binding affinities from the bloodstream into 
extravascular tissue space.16,17  HSA is thought to facilitate drug permeation by passing 
through endothelial layers via caveolar-mediated transcytosis.18,19 As one of most 
abundant proteins in the plasma (35−50 mg/mL) ,20 HSA forms aggregates reversibly and 
can accumulate passively in tumor tissue due to the enhanced permeability and retention 
(EPR) effect.21,22 In this regard, we note that HSA-based formulations have been 
characterized as nanoparticles ex vivo, but are thought to disperse into monomeric form 
soon after entering the bloodstream.23 This suggests that the pharmacokinetic properties 
of HSA may be tailored by judicious structural changes. 
 Interest in albumin-based drug delivery has been increasing due to the favorable 
pharmacology of HSA, its low immunogenicity, and its current availability in 
recombinant form. A well-known example of albumin-based formulation is HSA-bound 
paclitaxel (Abraxane®), currently being used for the treatment of several late-stage 
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cancers.24,25,26 Paclitaxel (PTX) is a powerful antimitotic that induces apoptosis in rapidly 
dividing cells;27 however, its therapeutic efficacy has been compromised by poor water 
solubility or by surfactants with peripheral side effects (e.g., Cremophore EL).28,29,30 The 
clinical success of Abraxane® confirms the benefits of HSA as a carrier of poorly soluble 
drugs like PTX; nevertheless, adverse side effects such as moderate neuropathy and 
neutropenia persist,26,31,32 indicating the need to further optimize drug loading and 
delivery. 
 PEGylated HSA has been prepared by conventional amide ligation, and shown to 
provide significant enhancements in its pharmacokinetic profile for drug delivery.33 
However, most studies have been conducted by modifying the acidic or basic residues on 
albumin, and the poor regioselectivity of amide-based ligations render these formulations 
vulnerable to unintended changes in structure or colligative properties. For example, N-
PEGylation reduces the volume of the hydrophobic binding cavity in the second R-helix 
domain, despite overall retention of HSA size and shape.34 
 Both HSA and its congener bovine serum albumin (BSA) possess a free thiol 
residue at Cys-34, which presents the option of site-specific S-PEGylation using 
maleimide chemistry.35,36 S-PEGylation of albumins can be performed with minimal 
perturbation to pre-existing disulfide bridges with subsequent retention of protein 
structure, as demonstrated in the case of PEG-(C34)BSA,35 and can increase its 
circulation lifetime relative to unmodified albumins, as demonstrated in a rat model with 
PEG(C34)HSA.36 These reports indicate that S-PEGylation at Cys-34 is an appealing 
alternative to amide-based ligations for developing albumin-based carriers with tailored 
pharmacological properties. It is worth mentioning that maleimide-based reagents have 
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also been developed for PEGylation across disulfide bonds,37,38 but are not immediately 
relevant for proteins bearing free thiols. 
 In this article we characterize the carrier properties of two mono-PEGylated HSA 
derivatives with site-specific conjugation at Cys-34, prepared on a multigram scale using 
maleimide-terminated mPEG chains having molecular weights of 5 and 20 kDa. S-
PEGylation produces minimal perturbations in conformation or solubilization of PTX, 
but significantly increases HSA's propensity to self-assemble into protein nanoparticles 
as characterized by nanoparticle tracking analysis (NTA). We also investigate the 
permeation of PTX through monolayers of human umbilical vascular endothelial cells 
(HUVEC) and brain microvascular endothelial cells (hCMEC/D3) with and without 
PEG(C34)HSA conjugates, and evaluate the therapeutic efficacy of PTX-loaded 
PEG(C34)HSA against MCF-7 breast cancer cells relative to native HSA (n-HSA). We 
find that C34-PEGylation has essentially no negative impact on PTX loading and 
subsequent permeation across cell monolayers. On the other hand, PEG(C34)HSA 
conjugates provide substantial increases in the transport and cytotoxicity of PTX 
delivered to MCF-7 cells, with negligible toxicity from PEGylated HSA alone. 
 
4.2 Materials and Methods 
 
Materials  
 Recombinant HSA was obtained from GenLantis (San Diego, CA); mPEG-
maleimide was obtained from Laysan Bio (Arab, AL); hydrocortisone, Hank’s balanced 
salt solution (HBSS), polystyrene T-75 flasks, and Transwell permeable supports were 
95 
 
purchased from Sigma-Aldrich (St. Louis, MO). Paclitaxel was obtained from LC 
Laboratories (Woburn, MA); radiolabeled [14C]paclitaxel ([14C]PTX) was purchased 
from Moravek Biochemicals (Brea, CA).   DMEM media, penicillin/streptomycin, and L-
glutamine were obtained from Corning Cellgro (Manassas, VA); fetal bovine serum was 
obtained from Atlanta Biologicals (Atlanta, GA); MTT reagent was obtained from RPI 
(Mount Prospect, IL); EGM-2, EBM-2, and basic fibroblast growth factor were obtained 
from Lonza (Walkersville, MD). MCF-7 cells were obtained from the Purdue Center for 
Combinatorial Chemical Biology; HUVEC cells were obtained from the American Type 
Culture Collection (ATCC; Manassas, VA); hCMEC/D3 cells were provided by Dr. 
Pierre-Olivier Couraud at Institut Cochin (Paris, France). Phosphate buffer solution 
(PBS) was prepared by tenfold dilution from a concentrated stock containing 80 g NaCl, 
2 g KCl, 4 g Na2HPO4, and 2 g KH2PO4.  All solutions were prepared using initially 
deionized water using a Milli-Q ultrafiltration system from Millipore (Bedford, MA) with 
a measured resistivity above 18 MΩ∙cm, passed through a 0.22-μm filter to remove 
particulate matter.   
 
Gram and Multigram Synthesis of PEG(C34)HSA conjugates 
 In a typical reaction, powdered HSA (1.0 g, 15.1 µmol) was dissolved in 40 mL 
of sterilized PBS (adjusted to pH 6.5) in a 100-mL glass round-bottomed flask.  The PBS 
was passed through a 0.2-μm syringe filter prior to use, and the mixture was stirred for 15 
minutes.  mPEG5K -Mal (155 mg, 31 µmol) or mPEG20K-Mal (620 mg, 31 µmol) was 
dissolved in 10 mL of sterilized PBS (pH 6.5) and added in 1-mL portions over 1 minute 
to the stirred HSA solution.  The mixture was placed in a 37 °C bath and stirred for 20 
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hours, then cooled to room temperature. Solutions of S-PEGylated HSA were transferred 
to dialysis membrane tubings (MWCO 12.4 kDa for PEG5K-HSA; MWCO 50 kDa for 
PEG20K-HSA) and gently agitated in 500 mL of deionized water to remove salts and 
excess mPEG-Mal (2 rounds, > 1 h each).  Approximately 90% of each PEG(C34)HSA 
was set aside for cell culture studies; the remainder was subjected to additional dialysis 
for characterization. PEG(C34)HSA conjugates could be lyophilized and stored in the 
dark at 4 °C. 
 For PEG(C34)HSA conjugates prepared on a multigram scale, purifications were 
performed with an Amicon stirred ultrafiltration cell (180 mL) equipped with a cellulose 
membrane filter (100 kDa MWCO), both from Millipore. Reaction mixtures were 
concentrated to gelatinous slurries (ca. 10 mL) then redispersed in deionized water to 
maximum volume, and repeated for up to 6 cycles. The rate of filtration ranged from over 




 Matrix-assisted laser desorption ionization mass spectra (MALDI-MS) were 
obtained using an Applied Biosystems Voyager DE PRO spectrometer, equipped with a 
nitrogen laser (337 nm) and a time-of-flight mass analyzer.  Positive-ion MS were 
obtained in the linear mode using an accelerating voltage of 25 kV, grid voltage of 94%, 
and extraction delay time of 98 nsec.  The m/z range for this study was 10−100 kDa, 
using 150 laser shots per spectrum and sinapinic acid as the matrix material.  
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 Circular dichroism (CD) spectra were obtained using a Jasco J-810 
spectrophotometer. Protein samples were prepared in halide-free phosphate buffer and 
diluted to 1 µM. The instrument was flushed with nitrogen for 1 hour prior to use; spectra 
were collected in triplicate from 190−260 nm at a scan rate of 7 minutes at 25 °C, with 
data averaging performed after background subtraction. Attenuated total reflectance 
infrared (ATR-IR) spectra were acquired using a Nicolet Nexus 670 FT-IR, under 
constant nitrogen flow.  Samples were prepared by depositing 1 mL of solution onto the 
ATR crystal, then dried under a nitrogen stream until a thin film was obtained. The 
sample chamber was purged for 20 minutes prior to collecting data.  
 High-performance liquid chromatography (HPLC) analyses were performed on 
100-μL aliquots of PEG(C34)HSA after extensive dialysis, using an Agilent 1100 Series 
HPLC with a Zorbax XDB-C8 column (Agilent, 4.6 mm × 15 cm).  Gradient elutions 
were performed using 33−66% aqueous CH3CN with 0.1% trifluoroacetic acid (TFA) at a 
flow rate of 0.75 mL/min; the column was equilibrated at 33% CH3CN for at least 30 
minutes prior to sample injection. Proteins were detected by absorbance at 280 nm, with 
yields determined by peak area integration. Levels of free mPEG-Mal were determined 
by HPLC at 215 nm, using a Zorbax XDB-C8 column with a gradient elution of 35−45% 
CH3CN plus 0.1% TFA (5-kDa mPEG-Mal), or a Phenomenex C18 reversed-phase 
column (2.0 mm × 5 cm) with a gradient elution of 30−90% CH 3CN plus 0.1% TFA (20-
kDa mPEG-Mal), with calibrations against a reference sample. In both cases, the amount 






 Nanoparticle tracking analysis (NTA) was performed using a Nanosight LM-10 
system equipped with a blue laser (λ= 405 nm), with data analysis supported by NTA 
v.2.3.5.0033 (Build 16).39 NTA was performed using PBS (pH 6.5) stored in 
polyethylene containers. The imaging chamber was cleaned with acetone and a 
microfiber cloth prior to use, then washed with particle-free water until no background 
signals were observed. Water was removed from the NTA chamber with a sterile plastic 
syringe just prior to use, and replaced with protein solution (1.0−0.1 mg/mL). Three 
tracking videos were collected per sample; 50 μL of fresh solution was injected in 
between each run to prevent protein aggregates from settling, followed by a 60-second 
recording at a shutter speed of 700 and a gain of 400. The number of tracks per run varied 
from 300 to 2000, depending on concentration. Hydrodynamic size analysis was derived 
from number and volume particle distributions, with population samples based on the 
number of tracks accumulated over several runs. Optimized parameters for video analysis 
(advanced mode) include a detection threshold of 10, 9 × 9 blur setting, and automated 
settings for track length and minimum particle size. 
 
HSA−PTX Formulation 
 PTX-HSA formulations were produced from freshly prepared stock solutions of 
PTX in DMSO (585 μM) and PEG(C34)HSA or n-HSA in PBS adjusted to pH 6.5 (150 
μM). PTX solutions were diluted serially with PBS to concentrations at 40× above the 
target dose.  PTX and HSA stock solutions were then combined in a 1:1 v/v ratio (0.4 mL 
total) and allowed to stand for 4 hours at room temperature, prior to use. 10-μL aliquots 
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of HSA−PTX solution were added to 190 μL of cell culture media in 96 -well plates 
containing MCF-7 cells at 10−20% confluence. DMSO concen trations were 0.1% v/v or 
less. 
 
Cell Permeation Studies 
 HUVEC and hCMEC/D3 cells were cultured in T-75 flasks at 37 °C, 5% CO2, 
and 90% humidity.  HUVECs were cultured in EBM-2 supplemented with Lonza EGM-2 
SingleQuots®.  hCMEC/D3 cells were cultured in EBM-2 supplemented with 5% FBS, 
1× penicillin−streptomycin, 1 ng /mL basic fibroblast growth factor, 1.4 μM 
hydrocortisone, 5 μg/mL ascorbic acid, 1% chemically defined lipid concentrate, and 10 
mM  HEPES buffer.  After thawing, cells were passaged at least three times before 
transport studies with media changes every other day. 
 Transport studies were performed in the apical to basolateral direction in triplicate 
wells simultaneously.  HUVECs were seeded between passages 6−10, while hCMEC/D3 
cells were seeded at passages 34−42.  Cells were seeded onto collagen -coated, 0.4-μm 
polyester Transwells®, at a density of 50,000 cells/cm2 for HUVECs and 70,000 cells/cm2 
for hCMEC/D3 cells.  HUVEC and hCMEC/D3 cells were allowed to proliferate and 
differentiate for 7 and 14 days respectively, with exchange of cell culture media every 
other day. Confluent cell monolayers were washed twice with PBS then equilibrated for 
30 minutes in HBSS, just prior to permeability studies.  Formulations containing [14C]-
PTX were added to the apical side of the Transwell® plate, which was kept on a rocker 
tray as aliquots were removed from the donor compartment at 15, 30, 45, 60, and 90 
minute time points. Initial and remaining donor as well as cell lysate samples were also 
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taken for permeability and mass balance calculations. 100 μL samples were diluted in 4 
mL EcoLite® scintillation fluid and counted for 5 minutes on a Beckman Coulter LS 6500 







𝑆𝐴 × 𝐶0 × 60
 
where dM/dt (counts/min) is the steady-state rate of mass transfer, SA (cm2) is the surface 
area of the apical membrane, and C0 (counts) is the initial donor concentration. Studies 
were compared using an unpaired, two-tailed Student’s t-test. 
 
Cell Viability Assays  
 Mitochondrial oxidation assays using the tetrazolium dye MTT were performed as 
previously described40 but using MCF-7 breast cancer cells, which were cultured in T-75 
flasks and complete DMEM media with 10% fetal bovine serum (FBS), 1% L-glutamine, 
and 1% penicillin/ streptomycin prior to plating. In a typical experiment, 96-well 
microtiter plates (5,000 cells/well) were incubated overnight in 200 μL of media to 
approximately 10% confluence.  Solutions in each well were replaced the following day 
with 190 μL of fresh media and 10 μL of PTX-HSA formulation, followed by 5 days of 
incubation at 37 °C under a 5% CO2 atmosphere. The media was removed and replaced 
with 190 μL fresh media and 10 μL 0.5% MTT, incubated at room temperature for 14 
hours, then replaced with 200 μL DMSO for homogenization. Absorbance measurements 
were recorded on a VersaMax microplate reader at 570 nm with background subtraction; 
cell viabilities were normalized to a negative control group (having reached 70−90% 
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confluence over 5 days). Experiments were run in triplicate with errors representing one 
standard deviation; two-tailed probability values were obtained by Student’s t-test. 
 
 
4.3 Results and Discussion 
 
Synthesis and Characterization of PEGylated HSA Adducts 
Following an earlier reported procedure,36 PEG(C34)HSA adducts were prepared 
at 37 °C in mildly acidic PBS (pH 6.5) by combining n-HSA (25 mg/mL) with 2 or 4 
equivalents of 5-kDa or 20-kDa mPEG-Mal (Scheme 1). Maintaining a pH slightly below 
7 helps to keep HSA in conformations that shield its internal disulfide bonds from other 
solutes.41 Analytical samples of S-PEGylated HSA were obtained by HPLC purification, 
whereas protein mixtures synthesized on a multigram scale were separated from 
unreacted mPEG-Mal by stirred ultrafiltration. Recombinant HSA was used instead of 
plasma-derived HSA, which reduces the risk of infection from unknown viruses or prions 
that may be present in the latter.  Recombinant and plasma-derived HSA have been 
shown to be identical in structure.42  
MALDI-MS and analytical HPLC were used to assess the degree of PEGylation: 
n-HSA produced a strong peak at m/z 66,553,43 whereas PEG5K- and PEG20K(C34)HSA 
produced additional peaksets centered at 71,984 (+5,431 amu) and 87,694 (+21,141 
amu), respectively (Figure 4.1a‒c). HPLC analysis on dialyzed samples indicated that 
treatment of n-HSA (Rt 6.4 min) with two equivalents of 5-kDa mPEG-Mal supported a 
72% conversion into PEG5K(C34)HSA (Figure 4.1e), whereas treatment with two 
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equivalents of 20-kDa mPEG-Mal supported a 48% conversion into PEG20K(C34)HSA 
(Figure 4.1f). The conversion efficiency was not affected by changes in reaction time, 
temperature or pH, but increasing the amount of 20-kDa mPEG-Mal to four equivalents 
increased the conversion of PEG20K(C34)HSA to 77%. It should be noted that the HSA 
was not pretreated with reducing agents, which can further optimize maleimide addition 
to free cysteines;44 therefore, the yields reported here should be viewed as a lower limit.  
We also note that ultrafiltration of PEG(C34)HSA from excess mPEG-Mal on a 
multigram scale was initially tedious due to the high viscosity of the retentate but became 
more efficient after several washings, with less than 1 wt% mPEG after six cycles 
according to HPLC. All subsequent studies using PEG(C34)HSA were performed with 
protein mixtures prepared from a 2:1 ratio of mPEG-Mal to n-HSA, and purified by six 









Scheme 4.1.  Synthesis of PEG(C34)HSA using 5- or 20-kDa mPEG-maleimide (Mal); 









Figure 4.1.  (a‒c) MALDI-MS analysis of n-HSA (m/z ~66.5 kDa), PEG5K(C34)HSA (m/z 
~72.0 kDa), and PEG20K(C34)HSA (m/z ~87.7 kDa); (d‒f) HPLC traces of n-HSA (as 








ATR-IR analysis confirmed retention of the PEG chain after exhaustive dialysis, 
with a strong peak at 1090 cm-1 corresponding to C−O stretching modes, and minimal 
differences in the amide peak region relative to n-HAS. Circular dichroism analysis of the 
PEG-(C34)HSA derivatives also indicated negligible changes in secondary protein 
structure relative to n-HSA, with very minor perturbations in 195−260 nm region (Figure 
4.2). We thus presume that S-PEGylation at Cys-34 has minimal influence on the 
secondary structure of HSA. 
 
Figure 4.2.  Circular dichroism spectra of n-HSA, PEG5K(C34)HSA (72% conversion), 
and PEG20K(C34)HSA (77% conversion). 
 
 
Effect of PTX‒HSA Formulations on Cell Viability 
 MCF-7 cells exposed to 10 nM PTX using a 30:1 mole ratio of PTX:n-HSA had 
a 1.7-fold greater therapeutic effect compared to 10 nM PTX in PBS without HSA (p < 
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0.05), whereas PTX formulated in a 10:1 mole ratio with n-HSA had 3.1-fold greater 
efficacy (p < 0.005; Figure 4.3).45 HSA without PTX (up to 100 nM) had a negligible 
effect on cell viability, confirming that its primary role is to increase the solubilization of 
PTX. The increased drug efficacy did not vary significantly for PTX:n-HSA ratios below 
10:1, implying an upper limit of 10 molecules of PTX per HSA carrier.  
 
Figure 4.3. The effect of formulating PTX (10 nM) with n-HSA on MCF-7 cell cultures, 5 
days post-treatment (N=3). PTX:n-HSA mole ratios range from 30 to 0.1, with [PTX] 
fixed at 10 nM. Significant changes in cytotoxicity marked with * (p < 0.05) or ** (p < 




 MCF-7 cells exposed to 10 nM PTX in a 10:1 mole ratio of PTX and 
PEG5K(C34)HSA or PEG20K(C34)HSA experienced similar increases in toxicity relative 
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to PTX alone (Figure 4.4).  As in the case with n-HSA, maximum efficacy was attained 
when PTX was formulated in a 10:1 mole ratio with PEG(C34)HSA derivatives 
compared to a 30:1 ratio, with no further improvements below that.  These results imply 
that the PEG chain does not inhibit the ability of HSA to bind and release PTX. Again, 
control experiments indicated that PEGylated HSA derivatives have no effect on cell 
viability. 
 MCF-7 cells were exposed to a range of PTX doses (0.3‒ 3 nM) formulated at 
10:1 mole ratios with n-HSA, PEG5K(C34)HSA, or PEG20K(C34)HSA. For intermediate 
PTX doses (6.6 nM), we observed that formulations with PEG20K(C34)HSA were at least 
60% more toxic than that of PEG5K(C34)HSA (p<0.05), and 80% more toxic than that of 
n-HSA (p < 0.01; Figure 4.5).  A linear interpolation of cytotoxicity data at 3.3 and 6.6 
nM yields IC50 values of 6.5, 5.9, and 4.7 nM when PTX is formulated respectively with 
10 mol% of n-HSA, PEG5K(C34)HSA, and PEG20K(C34)HSA, with the latter providing a 
nearly 40% increase in acute cytotoxicity relative to n-HSA. While the basis for the 
greater potency provided by PEG20K(C34)HSA has not yet been elucidated, we observe 
an intriguing correlation with changes in the self-association behavior of HSA induced by 







Figure 4.4. The effects of PTX (10 nM) formulated with PEG5K(C34)HSA or 
PEG20K(C34)HSA on MCF-7 cell cultures, 5 days post-treatment, with [PTX] fixed at 10 
nM (PTX:HSA = 30‒0.1; N=3). Significant changes in cytotoxicity marked with * and ** 
(p < 0.005). Error = 1 stdev. 
 
 
Figure 4.5. Cytotoxicity of PTX (0.3‒33 nM) formulated in a 10:1 mole ratio with n-HSA, 
PEG5K(C34)HSA, or PEG20K(C34)HSA (MCF-7 cells, 5 days post-treatment; N=3). 





Effects of PEGylation and PTX on Protein Nanoparticle Formation   
 Nanoparticle tracking analysis (NTA) was used to measure the hydrodynamic size 
(dh) and concentration of submicron protein aggregates in PBS (pH 6.5).  In nearly all 
cases, multimodal distributions were obtained with a wide variance (range of 100‒400 
nm); however, a comparison between datasets revealed clear differences in population 
sizes. At high protein concentration (1 mg/mL or 13‒15 µM), mixtures containing 
PEG5K- and PEG20K(C34)HSA formed several times more nanoparticles than n-HSA 
(Figure 4.6a), while their dh and volumetric mean values (dvol) remained roughly the same 
(Table 4.1).  At tenfold lower concentration (0.1 mg/mL or 1.3‒1.5 µM), suspensions 
with PEGylated HSA again showed a higher number of nano-aggregates relative to pure 
n-HSA (Figure 4.6b).  Although these concentrations are substantially higher than those 
used in the cytotoxicity assays, they show that S-PEGylation promotes HSA nanoparticle 
formation. It is worth noting that dynamic light scattering analysis of PEG20K(C34)HSA 
at 0.01 mg/mL also indicates nanoparticle formation (dh = 30‒80 nm), whereas n-HSA at 
the same concentration is essentially monomeric.36 
 The effects of PEGylation on the spontaneous formation of HSA nanoparticles 
were also evident for excipients formulated with PTX at a 10:1 mole ratio.  At low carrier 
concentration (0.1 mg/mL), mixtures with PEG5K- and PEG20K(C34)HSA formed 
aggregates with a narrower, bimodal distribution relative to n-HSA (Figure 4.6c).46 It is 
worth noting that the number of n-HSA and PEG20K(C34)HSA nanoparticles increased 
significantly in the presence of PTX, suggesting their formation to be driven partly by the 
cooperative association of hydrophobic domains. These results reveal the complex 
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interplay between protein concentration, PEG chain length, and the inclusion of PTX on 
the self-assembly of HSA nanoparticles in physiologically relevant conditions. 
 
 
Table 4.1. Statistical analysis of HSA nanoparticles by NTA. 
 
 
a Based on average number of tracks over three runs. b >100% above background. c Volumetric mean dvol = 




  Sample 
particle count   
(× 106 mL-1)a 
hydrodynamic size (nm) 
mode peaks b mean (dh) RSD (%)  dvol c RSD (%) 
1 mg/mL (no PTX)       
  n-HSA 258 
100‒160  
(broad), 235 
162 48 200 43 
  mPEG5K(C34)HSA 745 100, 320 152 51 195 45 
  mPEG20K(C34)HSA 671 140, 220 188 50 237 45 
0.1 mg/mL (no PTX)       
  n-HSA 92 
120, 150, 225, 
340 
192 37 219 35 
  mPEG5K(C34)HSA 221 125, 210, 290 166 48 206 43 
  mPEG20K(C34)HSA 157 120, 180, 290 182 48 227 44 
0.1 mg/mL (10:1 PTX:HSA)       
  n-HSA 123 90, 140, 220 189 65 264 54 
  mPEG5K(C34)HSA 161 90, 160 105 35 120 33 
  mPEG20K(C34)HSA 225 105, 210 141 43 173 40 






Figure 4.6. Hydrodynamic size analysis and number distribution of HSA nanoparticles by 
NTA, for mixtures comprised of n-HSA, PEG5K(C34)HSA, and PEG20K(C34)HSA in PBS. 
(a) 1 mg/mL (13‒15 µM), (b) 0.1 mg/mL (1.3‒1.5 µM), (c) 0.1 mg/mL with 10 equiv. 







Effect of Formulations on PTX Permeability 
 Monolayers of HUVEC and hCMEC/D3 cells were initially tested to examine the 
effect of n-HSA and mPEG(C34)HSA on PTX permeability, using [14C]-labeled drug.  
HUVEC monolayers are used to model the peripheral vasculature, whereas the 
hCMEC/D3 monolayers are representative of the blood‒brain barrier. 47,48  Studies were 
run at 1 μM [14C]-PTX alone and in 10:1 mole ratio with n-HSA or mPEG(C34)HSA, 
preceded by a 4-hour pre-equilibration period for the cell monolayers (Figure 4.7).49 The 
HSA formulations did not produce significant differences in [14C]-PTX permeation 
across either cell monolayer, which suggests that the binding and permeation of free PTX 
may be reversible. However, HUVEC monolayers exhibited significantly faster 
permeability rates, implying that PTX permeates more readily into the vascular periphery 
relative to the brain.  This is expected, as hCMEC/D3 cells express high levels of efflux 







Figure 4.7. Permeability of 1 μM [14C]-paclitaxel across hCMEC/D3 and HUVEC 
monolayers. Studies were run in triplicate simultaneously using a 10:1 mole ratio of 
PTX:n-HSA or PEG(C34)HSA (error = 1 stdev). 
 
 
 The effect of PTX concentration on HSA-mediated permeability was also 
investigated.  Papp values across HUVEC monolayers were initially obtained at 0.5, 1, 10, 
and 25 μM PTX in a 10:1 mole ratio with n-HSA or PEG(C34)HSA, following pre-
equilibration. Studies conducted at 0.5 and 1 μM PTX contained only [14C]-labeled drug, 
whereas higher concentrations were made from unlabeled drug supplemented with 1 μM 
[14C]PTX. At low solute concentrations, n-HSA appears to provide greater permeability 
then either PEG5K(C34)HSA or PEG20K(C34)HSA, but at higher concentrations no 
significant differences are observed (Figure 4.8a). The effect of drug‒carrier ratio on 
permeability was also examined at a 5:1 ratio of PTX to n-HSA or PEG(C34)-HSA 





































Figure 4.8. Effect of solute concentration on HSA-mediated HUVEC permeability. (a) 
Papp of [14C]-PTX using a 10:1 mole ratio of PTX to HSA carrier; (b) Papp of [14C]-PTX 
using a 5:1 mole ratio of PTX to HSA carrier. Permeability studies were run in triplicate 
simultaneously; differences between carriers marked with * (p < 0.05) or ** (p < 0.01). 
Error = 1 stdev. 
 
 
 While Papp is useful for delineating possible changes due to partitioning, 
diffusivity, or variations in free drug for each formulation, it only represents average 
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drug flux (Papp × C0), which represents the actual amount of drug transferred across the 
endothelial barrier and is a reliable metric for estimating blood levels. Since flux is 
concentration-dependent, it better illustrates the effects of solubilizing formulations than 
the relatively small changes in Papp. As expected, large increases in flux are observed for 
both 10:1 and 5:1 mole ratios of PTX to n-HSA or its S-PEGylated conjugates (Figure 
4.9). Again, S-PEGylation had little to no impact on drug transport, with minor 
differences attributable to the limited precision typically observed in permeation studies. 
This establishes that C34-PEGylated HSA can increase PTX efficacy as shown above, 








Figure 4.9. [14C]-PTX flux through HUVEC monolayers using n-HSA or PEG(C34)HSA. 
(a) 10:1 molar ratio of PTX to HSA carrier; (b) 5:1 molar ratio of PTX to HSA carrier. 
Permeability studies run in triplicate simultaneously; differences between carriers 
marked with * (p < 0.05) or ** (p < 0.01). Error = 1 stdev. 
 
 The enhanced efficacy of PTX formulated with PEG5K- and especially 
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also observe that S-PEGylation increases the number of HSA nanoparticles (up to 1.8-
fold) relative to n-HSA, particularly in the presence of PTX. While further research is 
needed to establish the basis for therapeutic enhancement, we consider the following as 
plausible factors for the observed phenomena: 
1. While the 5- and 20-kDa PEG chain attached to Cys-34 do not disrupt the tertiary 
structure of HSA, they may reduce its strength of association with bound PTX by 
increasing its conformational lability;  
2. Changes in the conformational stability of S-PEGylated HSA may also affect the 
stability of their aggregates in endosomes, with greater PTX release to the 
cytoplasm after uptake; 
3. The PEG chains may promote the nano-emulsification of HSA and PTX,46 into 
forms that are favorably transported by albumin receptors. 
 In short, while the prescribed benefits of protein PEGylation such as extended 
stability and circulation times in the bloodstream are well appreciated,12-15 there appear to 
be additional factors that may contribute toward favorable pharmacokinetics and drug 





 We have established that formulation of PTX with PEG5K(C34)HSA and 
especially PEG20K(C34)HSA enhances its acute toxicity against MCF-7 breast cancer 
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cells relative to native HSA carriers, while retaining high levels of permeability across 
monolayers of HUVEC or hCMEC/D3 cells. The latter has important ramifications on 
the bioavailability of PTX administered by non-intravenous mechanisms, as well as its 
extravasation into diseased tissue. C34-PEGylation has a notable influence on the size 
distribution of HSA nanoparticles, which may be partly responsible for the increased 
cytotoxicity of the PTX payload.51 Future studies are needed to generalize the therapeutic 
and pharmacokinetic enhancements of PEG(C34)HSA-mediated uptake for different 
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CHAPTER 5. CHARACTERIZATION, FORMULATION, & 




The 2014 Ebola outbreaks in West Africa have reinforced the concerns over high 
mortality and morbidity associated with pathogenic epidemics, particularly with yet 
unmet therapeutic viral entities.1  This outbreak was just the most recent in a number of 
outbreaks worldwide caused by a number of different infectious pathogens.  These 
outbreaks also lead to significant concerns about the potential of infectious pathogens to 
be weaponized and to be utilized in warfare.2 Thus, there has been an urgent need placed 
on the search for therapeutic agents that may serve as countermeasures to mitigate 
pathogenic agents exploited for terror or warfare applications.  In addition to Ebola, a 
number of other viral pathogens have been identified as high risk agents for 
weaponization and potential use in malicious manners including the encephalitic 
alphaviruses including the Venezuelan (VEEV), Eastern Equine (EEEV) and Western 
Equine (WEEV) encephalitic viruses.2 Universal to many of these high morbidity and 
mortality associated viruses is that their disease inducing pathogenesis relies on the host 
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cell entry and intracellular trafficking via endocytosis and subsequent activation within 
the endolysosomal compartments.3,4  
The combined research efforts of the investigative team have been focused on the 
development of an agent known to inhibit a critical protein, Vacuolar-ATPase (V-
ATPase) that acidifies the endolysosomal vesicles and activates the virus. Briefly, the V-
ATPase is a proton transporter which utilizes ATP to move protons against a 
concentration gradient into vesicles within the cell, resulting in reduction of pH within 
the vesicle.3  This low pH leads to a cascade of enzymatic activity and formation of the 
lysosome.  However, for many viruses, this low pH is necessary to trigger membrane 
fusion, unloading of viral RNA, and replication after endocytosis.4 We have investigated 
the development of saliphenylhalamide (SaliPhe), a potent analog of salicylihalamide that 
is a natural product known to act as a V-ATPase inhibitor.5,6 Therefore, 
salipenylhalamide may be effective at stopping replication of many viruses that utilize 
this mechanism to trigger unfolding.  It should also be noted that V-ATPase inhibition is 
currently also being investigated for treatment of osteoporosis and cancer.5-7  
 
While there has been some investigation into in vitro and in vivo efficacy of 
SaliPhe, less research has been conducted into its physicochemical properties, 
pharmacokinetics, and overall druggability.  With a molecular weight of 459.5, SaliPhe is 
under the 500 MW cutoff often associated with steep drop-offs in uptake and permeation 
rates that increase intracellular accumulation and drug distribution.8  In addition, it’s 
predicted polar surface area is only 96 Å2¸which is well below the cutoff of 140 Å2 for 
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peripheral permeation and just over the cutoff for uptake into the brain 90 Å2.9  SaliPhe 
has an AlogP of 4.5, which, while at the high end, is within the druggable range for 
pharmaceutical compounds.  Favorably, this high AlogP may also lead to increased 
distribution into the brain.10  Current limitations with SaliPhe are predicted to be 
solubility related.  In vivo efficacy studies suggest 7 mg/kg to be the efficacious 
intraperitoneal dose.11  With a predicted solubility of 0.2 μg/mL at physiological pH, the 
drug is unlikely to reach efficacious levels without an exposure enhancing formulation.   
 
Here we look to elucidate the relevant physicochemical properties of SaliPhe and 
to utilize these properties to guide formulation development.  Formulations with enabling 
properties were screened on in vitro cell models to assess changes in permeability and 
cytotoxicity.  Finally, testing was conducted on promising formulations for 
pharmacokinetics, biodistribution, toxicity, and efficacy in murine models. In addition, 
we proposed to characterize the physicochemical properties of structurally related 
SaliPhe analogs that were being developed to overcome several SaliPhe limitations for 
therapeutic utilization.  SaliPhe has been previously investigated for other chronic 
indications, although the drug was not advanced to the market due to druggability and 
toxicity concerns.11  These analogs may allow for safe and efficacious acute use of the 





The tasks that were conducted at Purdue included:  
1. SaliPhe ADME/T Assays 
2. Performance of Physicochemical and Preformulation Studies and  
3. Plasma PK for 3-5 formulation/prodrugs in rats and biodistribution in mice for 
2 formulations/prodrugs.  Note: Biodistribution studies were conducted in 
conjunction with the University of Louisville to ensure that the same mice that 
the efficacy studies were performed in were used to measure distribution.   
 
Initially we began early analysis to perform physicochemical analysis then made 
stable, solubility enabling formulations followed by investigation of the permeability of 
SaliPhe, and associated analogs, alone and in formulations across in vitro barriers of 
relevant cell models. This included human epithelial colorectal adenocarcinoma cells 
(Caco-2),12-14 human umbilical vein endothelial cells (HUVEC),15 hCMEC/D3 (human 
cerebral microvascular endothelial cell),16-19 and novel direct coculture and triculture in 
vitro models of the blood brain barrier (BBB) recently developed in the Knipp laboratory.  
 
In latter studies, two formulations of SaliPhe and one of a SaliPhe prodrug were 
submitted for rat PK analysis.  In addition, one biodistribution study was performed at 
Louisville and the organs were collected and submitted for bioanalysis at the Purdue 




5.2. Materials and Methods 
Materials 
Poloxamer 407, Poloxamer 188, Kolliphor EL, Kolliphor RH 40, Kolliphor HS 
15, Kollidon 25, Kollisolv PEG E 400, propylene glycol, hydroxpropyl-β-cyclodextrin, 
tween 80, d-alpha tocopheryl polyethylene glycol 1000 succinate, acetonitrile, Hank’s 
balanced salt solution (HBSS), phosphate buffered saline (PBS), Dulbecco’s Modified 
Eagle’s Medium (DMEM), fetal bovine serum, penicillin-streptomycin, non-essential 
amino acids, L-glutamine, hydrocortisone, type I rat tail collagen, polystyrene T-75 
flasks, and Transwell permeable supports were purchased from Sigma-Aldrich (St. 
Louis, MO). EGM-2, EBM-2, and basic fibroblast growth factor were obtained from 
Lonza (Walkersville, MD). Chemically defined lipid concentrate was purchased from 
LifeTechnologies (Carlsbad, CA). Human astrocytes, human pericytes, astrocyte 
medium, and pericytes medium was purchased from ScienCell (Carlsbad, CA). Caco-2 
and HUVEC cells were obtained from the American Type Culture Collection (ATCC; 
Manassas, VA); hCMEC/D3 cells were provided by Dr. Pierre-Olivier Couraud at Institut 










HPLC-Samples were run on an Agilent 1100 HPLC.  A 1.5 mL/min 50:50 
Acetonitrile:Water isocratic method was used for 10 minutes with a retention time of 6.9 
minutes.  An Agilent Eclipse XDB-C18, 5 μm, 4.6 x 150mm column with Security 
Guard-C18, 4 x3.0mm guard column was kept at 40oC.  UV detection was at 280 nm. 
Injections of SaliPhe alone were 100 μL/sample, formulated samples were 5 μL/sample. 
 
Powder X-ray Diffraction 
To assess crystallinity of the SaliPhe received, approximately 30mg was used for 
testing with Powder X-ray Diffraction (PXRD) on a Rigaku SmartLab XRD system.  
Sample was added onto a sample holder and gently crushed and flattened.  Intensity was 
then measured from 5 to 40 degrees (2θ).   Step size was 0.02 degrees at a speed of 40 
θ/minute. Voltage and current used were 40mV and 44mA respectively. 
 
Differential Scanning Calorimetry 
Thermal analysis was conducted on a TA Instruments Q1000 to confirm PXRD 
results and establish a melting point.  2.5 mg of sample was first hermetically sealed into 
an aluminum pan.  Changes in heat flow were measured from 25-350oC at a rate of 
10oC/minute. N2 was used as a purging gas and indium was used for calibration. 
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Octanol:Water Partition Coefficient 
Approximation of LogD was conducted in 0.1N HCl, (~pH 1), 10μM Acetate 
Buffer pH 4.5, and pH 7.4 PBS.  Prior to studies, 50mL of each aqueous solution was 
equilibrated with 50mL 1-octanol for 24 hours.  Approximately 1mg SaliPhe was then 
added to 500μL of each of the pre-equilibrated 1-octanol solutions.  After dissolution of 
the SaliPhe, 500uL of pre-equilibrated aqueous buffer was added and vortexed for 2 
minutes.  Samples were allowed to equilibrate overnight before samples from each phase 
were run according the HPLC method above with 1-octanol samples diluted 50 times in 
DMSO.  LogD was calculated by taking: 
 





Polymer Formulation Solubility Assessment 
To estimate solubility in a number of polymer solutions, 10% solutions were first 
made up by heating reagents to 50oC on a hotplate and incorporation by vortexing for up 
to 15 minutes.  SaliPhe in 100% DMSO was then spiked into each of the polymer 
solutions and vortexed for 5 minutes.  Following vortexing, samples were allowed to 
equilibrate for 90 minutes followed by a 15 minute centrifuge at 13,000 RPM.  The 




Polymer Formulation Stability 
Stability of formulations which lead to satisfactory increases in solubility were 
further characterized based on stability.  Samples were stored at 0, 25, and 37oC for one 
week in silanized inserts.  Samples were taken multiple times on the first day followed by 
once each additional day Stability was estimated based on changes in AUC after triplicate 
injection according to the HPLC method above. Before each sample was run, silanized 
inserts were centrifuged at 13,000 RPM for 15 minutes and supernatant was removed. 
Additional stability studies were conducted for SaliPhe alone in 0.1N HCl, pH 4.5 10mM 
acetate buffer, and PBS. 
 
Emulsion Formulation 
An emulsion formulation was made as an alternative dosing strategy for SaliPhe.   
Emulsion formulations were kept simple with a single aqueous phase (PBS), oil phase 
(Labrafil or Capryol), and surfactant (Solutol HS 15, Cremophor EL, Lecithin, 
Transcutol, Labrasol, Propylene Glycol).  Emulsions were made by first dissolving 
SaliPhe into the oil phase.  The surfactant(s) were then added and vortexed for 1 minute.  
PBS was then added to the oil/surfactant and again vortexed for 1 minute.  Vortexing was 
followed by microtip sonication for 1 minute.  The sample was then vortexed until 
homogeneous.  Formulations were then assessed based on translucence which was used 
to determine the ability of the formulation to both solubilize SaliPhe and form an 
emulsion.  Next, the formulations were left for 5 days at room temperature to assess the 
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physical stability.  Additional physical stability was conducted through an overnight 
freeze and thaw.  Finally, viscosity was assessed at room temperature.  It was determined 
through consolation with animal care that solutions more viscous than propylene glycol 
may be lethal to the rodents in pre-clinical studies, therefore, only those that were 
significantly less viscous by eye were used for further testing according to the Purdue 
Animal Care and Use Committee (PACUC) and the approved ACURO form that was 
submitted.   
 
Cell Culture 
Caco-2 cells were cultured in DMEM supplemented with 10% FBS, penicillin-
streptomycin, L-glutamine, and non-essential amino acids.  While culture flasks were not 
prepped, Transwells were coated with 65μL/well of 1mg/mL type I rat tail collagen in 
60% ethanol and left to evaporate for at least 4 hours.  Caco-2 cells were seeded at 
75,000 cells/cm2 and grown for 21-28 days before permeability studies were conducted.  
Human Umbilical Vascular Endothelial cells (HUVEC), mimicking the peripheral 
vasculature for organ distribution, were cultured in EBM-2 supplemented with EGM-2 
bulletkits.  HUVEC flasks were precoated with 1 μg/cm2 fibronectin.  Transwells were 
coated with 65μL/well of 1mg/mL type I rat tail collagen in 60% ethanol and left to 
evaporate for at least 4 hours.  HUVEC cells were seeded at 50,000 cells/cm2 and left to 
proliferate/differentiate for 7 days prior to studies. 
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hCMEC/D3 cells were cultured  in EBM-2 supplemented with 5% FBS, basic 
fibroblast growth factor, chemically defined lipid concentrate, HEPES buffer, ascorbic 
acid, penicillin streptomycin, and hydrocortisone.  hCMEC/D3 flasks were precoated 
with 6 mL of 150μg/mL of type I rat tail collagen in water.  Transwells were coated with 
65μL/well of 1mg/mL type I rat tail collagen in 60% ethanol and left to evaporate for at 
least 4 hours. hCMEC/D3 cells were seeded at 100,000 cells/cm2 and grown for 7 days 
before studies. 
Human astrocytes were grown in ScienCell’s complete astrocyte medium.  Flasks 
were coated as recommended with 2 μg/cm2 Poly-L-Lysine.  Transwells were coated with 
5 μg/cm2 to promote proliferation and differentiation. Astrocytes were seeded at 40,000 
cells/cm2 and grown 2 days before culture with additional cell lines. Human Pericytes 
were grown in a similar fashion with the exception of utilization of ScienCell’s complete 
pericyte medium. 
For hCMEC/D3 and human astrocyte coculture studies, human astrocytes were 
first plated as discussed above.  After two days in astrocyte medium, hCMEC/D3s were 
seeded directly on top of the astrocytes and grown for 7 days in hCMEC/D3 
supplemented EBM-2 before studies.  For triculture studies, 40,000 human 
astrocytes/cm2 were seeded in astrocyte media onto Transwells® (Corning-Costar) pre-
treated with 5μg/cm2 Poly-L-Lysine and grown for 2 days.  An additional 1 μg/cm2 Poly-
L-Lysine was then added to the top of the astrocytes followed by pericytes at a density of 
40,000 cells/cm2.  After two additional days of growth, 15 μg/cm2 type I rat tail collagen 
was added followed by 80,000 hCMEC/D3 cells/cm2. The triculture was grown for 7 
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more days with hCMEC/D3 supplemented EBM-2 in the apical compartment and 
astrocyte medium in the basolateral compartment before permeability studies were 
conducted.  It should be noted that the culture conditions were optimized under separate 
studies in our laboratory and have been disclosed via a provisional patent application. 
 
All cells were grown in 5% CO2, 37oC, and 95% RH.  Passages were conducted 
between 80 and 90% confluence.  Cells were limited to passage 50 for Caco-2s, passage 
12 for HUVECs, passage 45 for hCMEC/D3s, passage 15 for human astrocytes, and 
passage 12 for human pericytes. 
 
Permeability Studies 
All permeability studies were conducted statically in triplicate on 0.4μm 
polyethylene 12-well Transwell supports.  Prior to studies, media was removed and cells 
were washed twice with PBS.  Cells were subsequently equilibrated in HBSS for at least 
20 minutes.  SaliPhe solutions were then added to the donor compartment.  Receiver 
compartments contained vehicle used in donor.  Samples were taken at 30, 60, 120, and 
180 minutes as well as donor C0 and C180 minutes samples. 200μL samples were taken from 
basolateral compartment while only 100 μL samples were taken from the apical 
compartment.  Sample volume was replaced with blank vehicle after each time point, and 
the lost mass was accounted for in the permeability calculation.  Samples were run on 
HPLC according to method above with 100 μL injections for receiver compartment 
137 
 
samples, 50 μL for donor compartment samples, 100 μL injections for SaliPhe alone C0, 
and 5 μL for solubility enabled formulation C0.  Permeability coefficients (cm/s) were 
obtained through the following equation: 
𝑃𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 =  
𝑑𝑀
𝑑𝑡




 is the rate of SaliPhe or prodrug transfer across the cell layer, 𝐶0 is the initial 
donor concentration, and  𝑆𝐴 is the surface area of the Transwell® filter support and 60 
converts units in cm/min to cm/s. 
 
In Vivo Rat PK Studies 
 Pre-clinical rat PK studies were conducted according to the Purdue Animal Care 
and Use Committee (PACUC) and the approved ACURO submitted protocols with two 
SaliPhe formulations (3.5mg/mL SaliPhe in 2% P407 and in the F22 emulsion) as well as 
OM510 in 2% P407.  Studies were conducted on rats of approximately 250g and utilized 
the BASi Culex-S “Rat-Turn” model.  Samples were analyzed by LC-MS/MS utilizing 
optimized protocols through the Purdue Metabolite Profiling facility, as we have utilized 
previously.20-22  
 
Noncompartmental pharmacokinetic data analysis was performed using PK 
Solutions 2.0 from Summit Research Services (Montrose, CO).  SaliPhe or OM510 
plasma concentration time data were input into the software and the resultant profiles 
were curve stripped to extract the PK parameters.  SaliPhe or OM510 plasma 
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concentrations below the limit of quantitation were set to zero for determination of PK 
parameters. 
 
5.3. Results and Discussion 
 
Powder X-Ray Diffraction (PXRD)  
PXRD was run on the samples to assess crystallinity of the SaliPhe batch samples 
obtained.  The sample appeared to be mostly amorphous as evidenced by a large 
amorphous halo.  However, small amounts of crystallinity may be indicated by small 
peaks in intensity, specifically around 18 degrees.  Due to concerns for material usage, 
replicates were not performed and confirmation of crystalinity was attempted by DSC. 
 
 

















Differential Scanning Calorimetry (DSC) 
The DSC shows a small endotherm at 110oC suggesting some crystallinity may be 
present and is melting, which could confirm the PXRD measurement.  However, it is also 
possible that desolvation of a residual solvent may be occurring.  This is followed by 
degradation at approximately 220oC.  Additional melts between 160oC and 210oC are 
speculated to be either small amounts of impurities or traces of potential enantiotropicly 
more stable polymorphs are formed and then melting.  Hot stage microscopy, 
thermogravimetric analysis, and potential variable temperature PXRD are recommended 
for future batch characterizations to decipher the nature of these transitions.  
 
 



















   








LogD   
Log D values were relatively unchanged across the various aqueous conditions 
with a pH range spanning between ~1 and 7.4, when assessed in 0.1N HCl, pH 4.5 
acetate buffer, and pH 7.4 PBS.  In addition, values between 4.64 and 4.76 suggest a 
highly lipophillic compound at physiological pHs found in the blood and along the 
gastrointestinal (GI) tract.  However, while high, it is in the druggable range suggested by 
Lipinski’s “Rule of 5”.  Conversely, these Log D’s lie outside the druggable range 
suggested by GSK’s 4/400 rule and Pfizer’s 3/75 rule which may indicate poor 
druggability and an increased toxicological risk respectively.23 One benefit of the high 
LogD is the potential for increased uptake into the brain which may be necessary for 
targeting encephalitic viruses like VEEV.9 
 
 
Figure 5.3. LogD values of Saliphenylhalamide.  Samples performed in triplicate, error 
bars represent 1 standard deviation. 
 











Polymer-Based Solubility Enhancement 
As suggested above, the solubility of SaliPhe may be rate limiting in its 
druggability.15,23,24 In order to potentially improve solubility through polymer 
complexation, a number of excipients were examined.  It was determined that for 
exposure enabled pre-clinical formulations, a formulation solubility of at least 875 μg/mL 
would be necessary.  Initial studies investigated solubilizing ability of 10% polymer.  
Table 5.1. Solubility of Saliphenyhalamide in 10% polymer or excipient solutions. 
Polymer  Solubility in 10% w/w Polymer:HBSS 
(μg/mL)  
Kolliphor EL  664  
Kollidon 25  194  
Kolliphor RH 40  >4000 
Poloxamer 407  >4000 
Kolliphor HS 15  3580 
Tween 80 3290 
Kollisolv PEG E 400  18  
Vitamin E TPGS 3780 
Propylene Glycol  11  
Poloxamer 188  24  
Hydroxypropyl-β-Cyclodextrin  24  
HBSS  5.3  




This study was able to eliminate several potential GRAS and Pharmaceutical 
R&D approved excipients from further utilization. We selected several other excipients 
based on their ability to generate a 4 mg/mL solution.  Minimization of excipient choices 
enabled a reduction in polymer excipient concentration and potential confounding 
polymer effects. The maximum solubility at 1% of the remaining polymers was then 
determined. 
 
Table 5.2. Solubility of Saliphenylhalamide in 1% polymer solutions. 
 
This study suggests that SaliPhe is most soluble in Kolliphor RH 40 and 
Poloxamer 407.  Poloxamer 407 was selected for further studies as it is much easier to 
handle and holds a stable solubility at 4oC, which would be important for storage of stock 
solutions.  Upon permeability testing in HUVEC cells, we did observe reduced 
permeability coefficients across for SaliPhe when formulated with P407 as opposed to 
RH40. We hypothesize that this may be due to polymer binding.  
Polymer  Solubility in 1% w/w Polymer:HBSS (μg/mL)  
Kolliphor RH 40 2260 
Kolliphor HS 15 200 
Poloxamer 407 2270 
TPGS  1060 




Figure 5.4. Apparent HUVEC permeability of 100ug/mL Saliphenylhalamide in 1 and 5% 
P407 and RH 40 formulations.  Studies were run in triplicate with error bars 
representing 1 standard deviation. 
 
Upon re-evaluation, we wanted to ensure that sufficient solubility of SaliPhe was 
maintained, thus we decided to use a 2% P407 solution for IP injection.  As a 500 μL 
injection is the maximum allowable injection for the rats, a 7 mg/kg dose required 
solubility of 3.5 mg/mL.  This was achievable with both 2% and 5% P407. A preliminary 
study conducted at the University of Louisville revealed that the 5% P407 may have 
potential adverse effects in rodents that were not observed with the 2% concentration.  
While manufacturer recommendations suggest 5% P407 formulations to be safe in 






























Stability of Polymer-Based Solubility Enhancing Formulation 
Similar to known stability issues of SaliPhe in acid, considerable degradation of 
P407 formulated SaliPhe still occurs.  Approximately 40% of the drug degrades in the 
first hour in 0.1N HCl.  It is unknown if further enzymatic degradation may occur in the 
stomach, however, the effect of pH alone may require co-administration with a basic 
buffer, or enteric coating for oral delivery.  These results reinforced our focusing on the 
IP and IV administration routes and revealed that the peroral administration route was not 
feasible in these early proof-of-concept studies.  
 
 
Figure 5.5. Acid degradation of Saliphenyhalamide in 2% P407 formulation. 
 
Further investigations were conducted to determine the stability of SaliPhe in rat 
plasma, as the rodent Culex® units collect blood samples overnight and maintain them at 













SaliPhe in 5% Kolliphor P407 Acid Degradation 
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diluted 50-fold into rat plasma and allowed to equilibrate for a number of different time 
points.  A marked drop in concentration (~50%) was seen after allowing the samples to 
equilibrate for 1 hour, however, it then held concentration for over 24 hours.  We 
hypothesized that this is due to binding of SaliPhe to serum proteins in the plasma.  A 
follow-up study revealed that an increased concentration of SaliPhe was obtained after an 
acetonitrile precipitation prior to analysis in the presence of plasma proteins.  Other than 
plasma protein association, SaliPhe was determined to be stable in rat plasma.  We 
accounted for this loss in PK studies. 
 
Figure 5.6. Plasma degradation of Saliphenylhalamide in 2% P407 formulation. 
 
Kolliphor P407 Permeability Studies 
Due to the combined issues of solubility enhancement, safety, and stability, a 














SaliPhe in 2% Kolliphor P407  Rat Plasma Stability 
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further preclinical investigation.  Initial studies were conducted on in vitro cell models to 
elucidate potential deposition as well as changes in permeability upon dilution.  
 
Caco-2 (human epithelial colorectal adenocarcinoma cells) 
Initial permeability studies were conducted in Caco-2 cells to assess the 
permeability of SaliPhe across a gastrointestinal (GI) barrier.  SaliPhe was added at 3, 
87.5, and 175 μg/mL for solubility enhanced formulations and 3 μg/mL for SaliPhe 
alone.  87.5 and 175 μg/mL were selected to mimic dilution into the blood, while 3 
μg/mL was run in 2% P407 and alone in HBSS to assess the effects of the formulation on 
permeability.   
 
Figure 5.7. Apparent Caco-2 permeability of unformulated Saliphenylhalamide and in 

































As can be seen in the figure above, it appears that the formulation does present a 
significant reduction in permeation rates, most likely due to SaliPhe binding with P407 
and minimizing the concentration of free drug that can readily permeate.  This 
phenomena has been observed in other systems, particularly with amorphous 
dispersions.24  Interestingly, at higher concentration of drug in P407, this effect wasn’t 
seen and in fact, the permeability coefficients at these higher concentrations was 
increased.  As oral dosing of SaliPhe is currently unlikely, no further examination was 
done. 
 
HUVEC (human umbilical vein endothelial cells) 
As SaliPhe is most likely to be dosed IV or IP, the permeability was measured 
across the HUVEC cell line, which is often used as a representative cell line for the 
peripheral capillaries, was assessed with the same formulations utilized in the Caco-2 cell 
line.  However, differences in permeability and permeation trends were seen.  First, 
permeability rates for SaliPhe through the HUVEC cell line was significantly faster than 
Caco-2 permeability (around 10-fold).  In addition, in the HUVEC cells, increased 
amounts of drug in the formulation didn’t seem to change the permeability of SaliPhe, 
and if anything led to decreases.  In fact the P407 formulations lead to reduced 
permeability across the HUVECs when compared to drug alone.  We hypothesize that the 
kinetics of binding with P407 may minimize the free drug concentration available for 
permeation.  We also caution that in vitro permeation rates are a guide and not reflective 




Figure 5.8. Apparent HUVEC permeability of unformulated Saliphenylhalamide and in 
2%P407 formulation. Studies were run in triplicate with error bars representing 1 
standard deviation. 
 
Blood-Brain Barrier Permeability 
A number of studies were conducted to determine the permeability of SaliPhe 
alone and in P407 formulations across BBB in vitro models.  All models included the 
hCMEC/D3 cell line, with coculture studies including direct contact culture with primary 
human astrocytes and the triculture model grown in direct contact with both primary 
human astrocytes and pericytes (IP Pending).  Current work in the Knipp lab suggests the 
co- and triculture models may serve as more physiologically relevant models for the in 
vivo BBB screening (manuscripts in preparation). Studies were conducted at 5 μg/mL 



































Figure 5.9. Apparent BBB permeability of unformulated Saliphenylhalamide and in 
2%P407 formulation.  Here, blue bars represent monoculture (hCMEC/D3 cells alone), 
red bars represent coculture (hCMEC/D3 cells grown on Human Astrocyte lawn), and 
green bars represent triculture (hCMEC/D3 cells grown on Human Astrocyte and 
Human Pericyte lawn). Studies were run in triplicate with error bars representing 1 
standard deviation. 
 
The study again suggests a potential decrease in permeability in P407 
formulations.  In addition, a non-significant decrease in permeability was seen with 
increased concentrations.  Interestingly, permeability was highly variable between the 
three models for studies of SaliPhe alone.  Further investigation must be conducted to 
determining the cause of this variability.  However, with the most physiologically 
relevant BBB triculture model there appears to be little permeability change in relation to 
concentration of SaliPhe or the presence of P407.  In addition, the permeability across the 































disposition into the brain may be permeability-limited under normal physiological 
conditions.  The in vivo BBB is disrupted in disease states from an inflammatory 
response, thus the results suggest that the permeation across the normal BBB will be 
reduced and may alleviate any potential off target effects that might arise. 
 
Emulsion Formulation 
A number of emulsion formulations were investigated as an additional means of 
solubility enhancement and improving drug delivery.  Formulations were selected based 
on transparency, stability, viscosity, and their ability to solubilize 3 mg/mL SaliPhe. 
Transparency was used as a criterion as it was the most rapid method to determine both 
solubilization and micelle formation.  In addition, high viscosity can result in animal 










Table 5.3. Saliphenylhalamide emulsion design of experiments.  Here, values 
represent percent of total formulation, Y implies yes formulation meets criteria, and N 
implies no formulation does not meet criteria. Green represents a formulation passing all 




As can be seen, only formulations F16, F22, and F23 were able to meet all of the 
criteria.  After discussion with animal care, it was determined that viscosity for F16 and 
F23 were high end and may cause some animal welfare concerns upon in vivo dosing. 
Therefore, the lowest viscosity formulation, F22, was selected. This emulsion consisted 




PBS Labrafil Capryol Solutol Cremophor EL Lecithin Transcutol Labrasol Propylene Glycol Stability Clarity Fluidity Acceptability
1 35 30 25 10 Y Y N
2 35 30 25 10 N Y -
3 30 30 27 13 N Y -
4 30 30 27 13 N N -
5 35 30 15 10 10 Y Y Y/N
6 35 30 25 10 N N -
7 35 30 20 10 5 N Y -
8 35 30 15 20 N Y -
9 35 40 15 10 N N -
10 40 35 25 N N -
11 60 10 20 10 N N -
12 35 30 15 10 10 N Y -
13 35 30 35 N Y -
14 40 20 30 10 Y Y N
15 45 20 35 Y Y N
16 50 20 30 Y Y Y
17 60 20 20 Y N -
18 55 20 25 Y N -
19 60 15 25 Y N -
20 60 15 25 N N -
21 60 15 20 5 N N -
22 55 15 30 Y Y Y
23 50 15 30 5 Y Y Y
24 50 15 25 10 N N -
% Total Formulation Comments
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In addition, the F22 micelles were analyzed by a Zetasizer to determine their size 
and zeta-potential.   As can be seen below, the micelles formed were relatively small with 
a diameter of only 22 nm.  This was unchanged when loaded with SaliPhe at 3 mg/mL.  
Finally, the micelles both, blank and SaliPhe-loaded, showed a relatively neutral zeta- 
potential.  This may lead to stability concerns, however, samples were stable for >1 week. 
 
Table 5.4. Characterization of blank and Saliphenylhalamide F22 emulsion formulations.  
  Properties Blank SaliPhe-loaded 
F22  Size (d, nm) 22.12 23.13 
Zeta potential (mV) -2.06 -3.97 
 
 
Emulsion Formulation Permeability Studies 
Based on time constraints, permeability studies of SaliPhe in the F22 emulsion 
were only measured across the HUVEC cell line to assess changes in the permeability 
coefficients with the formulation.  SaliPhe was run in F22 at 75, 150, and 300 μg/mL to 
predict permeability at 10, 20, and 40-fold dilution into the blood and compared to 3 
μg/mL SaliPhe alone.  Below we see that formulation with F22 led to approximately 5-
fold reduction in permeability of SaliPhe.  We hypothesize that this is likely due to the 
inability of SaliPhe to permeate the HUVEC cells while sequestered in the emulsifying 
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micelles.  While further work is required, it also may indicate that systemic distribution 
may be minimized based on the formulation in vivo. 
 
 
Figure 5.10. Apparent HUVEC permeability of unformulated Saliphenylhalamide and in 
F22 emulsion formulation. Studies were run in triplicate with error bars representing 1 
standard deviation. 
 
OM510 P407 Permeability Studies 
Preliminary studies were conducted to determine the permeability of OM510 in 
2% P407 across peripheral (HUVEC) and BBB (hCMEC/D3) cell models.  Similar to 
studies above, 2 μg/mL concentration represents drug alone, while the other 


































Figure 5.11. Apparent HUVEC and hCMEC/D3 monoculture permeability of 
unformulated Saliphenylhalamide prodrug OM510 and in 2% P407 formulation. Here, 2 
µg/mL samples represent unformulated while 10, 50, and 100 µg/mL samples are 
formulated in 2% P407. Studies were run in triplicate with error bars representing 1 
standard deviation. 
 
These results suggest that OM510 permeability is much different than that of 
SaliPhe.  First, permeability of OM510 appears to be approximately 10-fold faster when 
compared to SaliPhe. In addition, while the formulation with P407 shows similar reduced 
HUVEC permeability when compared to SaliPhe, no reduction is seen with the 































Plasma Protein Binding 
In order to determine potential protein binding, excess SaliPhe in DMSO was 
added to a 1% (w/w) solution of Human Serum Albumin (HSA) in PBS.  Samples were 
allowed to equilibrate for 3 hours then centrifuged for 15 minutes at 15,000 RPM.  The 
supernatant was then diluted 2-fold in acetonitrile to crash out plasma protein.  The 
sample was again given 3 hours to equilibrate before being centrifuged as above.  The 
supernatant was then analyzed by HPLC.  Results suggest that SaliPhe has a solubility of 
approximately 100 μg/mL in a 1% HSA solution, almost 20-fold higher than that of PBS 
alone.  This suggests SaliPhe may be highly protein bound in the plasma.  We 
hypothesize that an HSA formulation may allow for extended delivery and increased 
solubility in the blood.  This an area of ongoing research in our laboratory.8 
 
In Vivo Rat PK Studies 
 Finally, in order to determine the in vivo effects of SaliPhe formulation, three 
formulations were tested in the Culex NxT “Rat Turn” Model.  Studies consisted of 7 
mg/kg doses of SaliPhe in 2% P407, SaliPhe in the F22 emulsion formulation, and 






2% P407 and F22 Emulsion SaliPhe Formulation Rat PK Studies 
 The pharmacokinetic (PK) studies were conducted on SaliPhe in its polymer and 
emulsion formulations.  Samples were pulled at 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours.  
Eight mice were dosed at 7 mg/kg with on average approximately 500 μL 3.5 mg/mL 
SaliPhe in P407 (4 Rats) or 550 μL 3.0 mg/mL SaliPhe in the F22 emulsion formulation 
(4 Rats).  Both formulations showed rapid disposition with approximately 1 μg/mL 
remaining in the blood after 15 minutes.  PK parameters are shown below: 
 
Table 5.5. Rat pharmacokinetic parameters for 7mg/kg Saliphenylhalamide in 2% P407 and F22 
emulsion formulations.  C initial is initial concentration, AUC∞ is area under the curve 
extrapolated to infinity, Vd is volume of distribution, and CL is clearance.  P-values were 
determined with student’s T-test with n=4. 
 
 
As can be seen, insignificant changes (p=0.103) in the initial blood concentration 
were seen between the two formulations. However, the P407 formulation appears to be 
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quantitatively higher, where the values are most likely not statistically significant due to 
high variability within the sample size.  The P407 formulation did demonstrate a 
statistically significant higher AUC than the F22 formulation.  This may be explained by 
the higher clearance and lower half-life of the F22 formulation.  It is possible that due to 
the small size of the micelles that they are rapidly cleared before the drug can diffuse into 
the blood and eventually into the tissues.  Therefore, we suggest that the 2% P407 
formulation is likely to be the more likely translatable as it appears to have better 
solubilization through transient binding allowing disposition before clearance.  Individual 
PK plots are shown below as well as average PK plots over the first four hours as blood 
levels had reduced by over 99% within this time.  
 
 
Figure 5.12. Concentration vs. time plots of 4 rats injected with 7mg/kg 































Figure 5.13. Average first four hours for concentration vs. time plots of 4 rats injected 
with 7mg/kg Saliphenylhalamide in 2% P407. Error bars are 1 standard deviation. 
 
Figure 5.14. Concentration vs. time plots of 4 rats injected with 7mg/kg 

















































Figure 5.15. Average first four hours for concentration vs. time plots of 4 rats injected 
with 7mg/kg Saliphenylhalamide in F22 emulsion formulation. Error bars are 1 standard 
deviation. 
 
2% P407 OM510 Formulation Rat PK Study 
 Due to time constraints, OM510 was tested only with the more favorable 
formulation of 2% P407.  Again, studies were conducted in 4 mice with a 7 mg/kg 
SaliPhe dose (weight adjusted to account for increased molecular weight of prodrug).  
However, only a limited number of samples were allowed due to a restricted timeline.  
Therefore samples were only pulled at 0.25, 0.5, 1, and 2 hours.  Unfortunately, two 
hours did not allow for complete PK analysis as it appears a mixture of disposition, 
























In order to attempt to pull any useful data, the average SaliPhe PK plot was used.  These 
PK parameters are shown below: 
 
Table 5.6. Rat pharmacokinetic parameters for 7mg/kg OM510 in 2% P407 formulation.  C 
initial is initial concentration, AUC0→2hr is area under the curve for 0 to 2 hour time interval, Vd 
is volume of distribution, and CL is clearance.  Average is for n=4 rats. 
 
 
 While it is difficult to assess the actual parameters for comparison, a number of 
testable observations can be made that will enable further interpretation.  First, it appears 
that OM510 provides a higher initial SaliPhe concentration upon conversion of the 
prodrug, suggesting that it may slightly reduce disposition into the tissues.  In addition, 
OM510 gives a much higher AUC through the first four hours than seen with SaliPhe 
over 24 hours.  This may be due to reduced clearance, reduced disposition, or a 
combination of the two.  Finally, the results give a half-life of approximately 1 hour, 
which is significantly lower than that seen with SaliPhe in 2% P407.  However, it is 
speculated that disposition is still occurring and that the terminal phase, in which half-life 
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is better measured, has not yet been reached at 2 hours.  Individual and average PK plots 







































Figure 5.17. Average concentration vs. time plots of 4 rats injected with 7mg/kg OM510 
in 2% P407. Error bars are 1 standard deviation. 
 
In summary, the OMM 510 analogue may offer superior PK parameters and have 
an enhanced chance for translation into the clinic comparative to SaliPhe. Further 
research is required, but the development of additional prodrugs also may offer 
considerable promise for development. 
 
In Vivo Murine Biodistribution Studies 
 Several attempts were made to recover and quantitate the levels of SaliPhe in the 
tissue samples that were provided to us for the biodistribution study.  All sample 


























bioanalytical LC-MS/MS method used to analyze the PK samples above were utilized.  
However, we were unable to determine SaliPhe levels above the limit of detection in the 
study.  Upon reflection and discussion, it was concluded that a future biodistribution 
study will require using a two-week dosing regimen versus the single dose study that was 
performed here.  Based on the promising results with the OM510, we would recommend 
planning to perform the biodistribution study on this analogue versus SaliPhe in the 
future.  It appears that OM510 may be superior from a PK standpoint.   
 
5.4. Conclusions 
 The growing number of viral outbreaks around the globe and threat of 
weaponization of some of these viruses has lead to an uptick in the investigation of 
prospective antiviral therapeutics.  Due to its utilization in viral replication, the V-
ATPase represents a potential endogenous protein for antiviral drug targeting.  Previous 
studies have shown SaliPhe to be a potent inhibitor of the V-ATPase, however, these 
studies were done with little knowledge of the physicochemical properties in non-
pharmaceutically relevant formulations.5-7,25-27  Therefore, here we looked to characterize 
SaliPhe and formulate around its potential druggability concerns.  
After initial solid-state characterization, main druggability concerns focused on 
lack of solubility and acid liability.  SaliPhe was shown to have an equilibrium aqueous 
solubility of less than 10 μg/mL with a predicted solubility need of 3.5 mg/mL.  In 
addition, SaliPhe has a projected half-life in acid of less than two hours, which in 
combination of poor predicted GI permeation made oral dosing unviable at this time. 
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Therefore, solubility-enabling 2% P407 and F22 emulsion parenteral formulations were 
created to overcome these concerns.  These formulations were then subjected to in vitro 
and in vivo screens to determine their effectiveness.   
In vitro cell permeation screens showed poor permeability of both unformulated 
and formulated SaliPhe into the brain; however, HUVEC permeability suggested 
moderate permeation into the periphery.  In vivo murine biodistribution studies were 
conducted to confirm in vitro predictions, but tissue concentrations were below detectable 
limits.  Therefore, pharmacokinetic studies were conducted to determine relevant 
pharmacokinetic parameters.  Here, the 2% P407 formulation appeared to be the more 
druggable formulation with higher initial concentrations, AUC, volume of distribution, 
and a longer half-life. 
  Finally, OM510, a proprietary prodrug of SaliPhe, was formulated and assessed 
in in vitro and in vivo screens.  OM510 was synthesized to promote increased solubility 
and brain permeation.  Due to material and time concerns, characterization was not 
performed.  Initial in vitro permeability screens suggested that OM510 is much more 
permeable than the parent compound therefore it was moved into in vivo rat 
pharmacokinetic studies.  OM510 was dosed in the 2% P407 formulation as this 
formulation was more successful for the parent compound.  Murine pharmacokinetic 
studies supported in vitro studies suggesting that with a higher initial concentration, 
AUC, and volume of distribution OM510 may be a more druggable compound than the 
parent, Saliphenylhalamide. 
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